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ABSTRACT 
 
Keywords: Colon Cancer, Microarray Gene expression profiling, Gene ontology 
enrichment analysis, MicroRNA, System Biology, Bioinformatics, Gene 
signature, Cross-Validation, Diagnostic and Prognostic.   
 
Colorectal cancer is the third most common cancer and the leading cause of 
cancer deaths in Western industrialised countries. Despite recent advances in the 
screening, diagnosis, and treatment of colorectal cancer, an estimated 608,000 
people die every year due to colon cancer. Our current knowledge of colorectal 
carcinogenesis indicates a multifactorial and multi-step process that involves 
various genetic alterations and several biological pathways. The identification of 
molecular markers with early diagnostic and precise clinical outcome in colon 
cancer is a challenging task because of tumour heterogeneity. 
 
This Ph.D.-thesis presents the molecular and cellular mechanisms leading to 
colorectal cancer. A systematical review of the literature is conducted on 
Microarray Gene expression profiling, gene ontology enrichment analysis, 
microRNA and system Biology and various bioinformatics tools.   
 
We aimed this study to stratify a colon tumour into molecular distinct subtypes, 
identification of novel diagnostic targets and prediction of reliable prognostic 
signatures for clinical practice using microarray expression datasets. We 
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performed an integrated analysis of gene expression data based on genetic, 
epigenetic and extensive clinical information using unsupervised learning, 
correlation and functional network analysis. As results, we identified 267-gene 
and 124-gene signatures that can distinguish normal, primary and metastatic 
tissues, and also involved in important regulatory functions such as immune-
response, lipid metabolism and peroxisome proliferator-activated receptors 
(PPARs) signalling pathways.  
 
For the first time, we also identify miRNAs that can differentiate between primary 
colon from metastatic and a prognostic signature of grade and stage levels, which 
can be a major contributor to complex transcriptional phenotypes in a colon 
tumour.  
.  
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CHAPTER 1 INTRODUCTION 
1.1 Colon Cancer 
Colon cancer (CC) is the most common malignancies in the world and accounts 
for about 10% of all cancer deaths in both Europe and the USA. (Perez Villamil et 
al., 2012b). Regardless of advances in screening methods, diagnosis, and 
therapies, colorectal cancer is the third most common cancer and the fourth-
leading cause of cancer death worldwide (Greenlee et al., 2000). Till date, 
histopathological staging is the only prognostic classification method is used in 
clinical practices for the selection of patients for chemotherapy treatment. 
However, it has often occurred that cancer staging on the basis of pathological 
prognosis fails to predict recurrence accurately in many patients undergoing 
curative surgery for localized CC. In fact,  10%–20% of patients with stage II CC,  
and 30%–40% of those with stage III CC,  develop recurrence (Marisa et al., 
2013a). Extensive investigative studies on colon cancer for the discovery of 
molecular markers for characterization and prognosis revealed that microsatellite 
instability (MSI) is caused by defective function of the DNA mismatch repair 
(MMR) system and the only marker that was reproducibly found to be a 
significant prognostic factor in early CRC in both a meta-analysis and a 
prospective trial (Hutchins et al., 2011, Popat et al., 2005). Microarray gene 
expression profiling is a powerful tool for the identification of diagnostic and 
prognostic gene signatures. Supervised analysis of gene expression has been used 
to discover gene signatures to identify patients at risk of recurrence of colon 
cancer (Zlobec et al., 2010, Zhang, 2008, Yamasaki et al., 2007, Wang et al., 
2004, Tran et al., 2011). Therefore,  a number of studies have implemented 
microarray technology to investigate gene expression profiles (GEPs) in CC in 
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recent years,  but unfortunately none of the well-established gene signatures have 
been discovered that could be beneficial in clinical practice,  especially for 
predicting clinical outcome (O'Connell et al., 2010, Eschrich et al., 2005). For the 
precise drug targets, molecular homogeneity may be essential in order to identify 
specific biological pathways affected. Gene expression profiling based studies on 
CC have been only poorly reproducible largely because CC disease is composed 
of distinct molecular entities that may develop through multiple pathways on the 
basis of different molecular features (Kang, 2011, Jass, 2007, Marisa et al., 
2013a).  
1.2 Role of Microarray in Cancer Research 
Cancer is a clinically heterogeneous disease. During the past century, the clinical 
behaviour of various cancers was determined using histopathology analysis, a 
process that often lacks exact severity of cancers. Therefore,  the microscopic 
approach can only predict general categories of cancer and cannot reach high 
specificity and sensitivity prediction in clinical practice (Liotta and Petricoin, 
2000). So there is consistently need of novel methods and tools which can answer 
the heterogeneity of these tumours and complement histopathological evaluation 
to increase the specificity and sensitivity in cancer diagnosis and prognosis.  
The Central dogma of molecular biology elucidates that gene expression is a two-
step process in which genetic information is first transcribed into messenger RNA 
(mRNA) through transcription process followed by translation process into a fully 
functional form known as proteins, which are also a major structural component 
of the cell. There is strong understanding that all major cellular process is 
controlled by certain collective expressed genes,  therefore,  it is a great value to 
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analyse genome-wide mRNA level (Brown and Botstein, 1999). Advances in 
technology along with completion of Human Genome Sequence has offered new 
technology, DNA microarray technology. DNA microarrays have the ability to 
simultaneously analyse thousands of mRNA (gene expression level) genes in a 
given sample. The methodology used in this type of measurement generally 
known as gene expression profiling. The introduction of DNA microarray 
technology provided much-improved understanding of various cancers  and 
allowed researchers to analyse thousands of cancer genes along with their role in 
disease progression and their expression patterns linked to clinical phenotypes 
(Lonning et al., 2005). The DNA microarray technology also offers great benefits 
in terms of identification of gene signatures who have the ability to differentiate 
cancer from normal and metastatic tissues, capable of predicting outcomes and 
recurrence, and response to treatment. The technology also offers a great deal of 
potential for discovery of novel drug targets and improve our understanding of the 
disease causes and progression.    
1.2.1 DNA Microarray  
The idea behind DNA microarrays is a specific hybridization of complementary 
nucleic acid sequences between the two DNA fragments,  one is DNA 
microscopic spots attached to the solid surface and other is fluorescent labelled 
RNAs from target tissue (Southern et al., 1999). Generally, a DNA microarray 
consists of thousands number of DNA spots, known as probes or reporters or 
oligo, on a glass. The signal intensity of hybridization of each probe-target is 
quantified by detection of fluorophore should correlate to the abundance of 
mRNA in a target. There are generally two types of DNA microarrays based on 
the DNA fragment used in the constitution of arrays, oligonucleotide arrays and 
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complementary DNA (cDNA) arrays. In oligonucleotide arrays, probes are 
synthesizing directly on the surface of silicon water whereas cDNA array is 
prepared using polymerase chain reaction amplification of interesting genes from 
cDNA library.  
1.2.2 DNA Microarray Analysis   
A number of advance tools have been proposed recently for the analysis and 
interpretation of DNA microarrays data. These tools are commonly divided into 
two major categories, supervised learning (classification) and un-supervised 
(clustering) learning methods. The goal of supervised learning methods is to 
identify gene expression patters e.g. gene expression signature,  which can be used 
for the classification of unknown samples according to their biological or 
functional characteristics (Golub et al., 1999). So, supervised learning methods 
provides an opportunity to integrate knowledge of class label into analysis for the 
classification of samples. Hence, in a given microarray data set consisting of gene 
expression matrix and class label, a subset of most diagnostically discriminatory 
genes can be selected by building a predictive model, also known as classifiers 
e.g. SVM (support vector machine) and K-NN (K- nearest neighbours). The 
underlying concept of these classifiers is to take input expression matrix of the 
pre-selected set of genes of unknown samples as an input and predicts the class 
label of each sample. Supervised learning is largely used for two class problems 
e.g. cancer versus normal, or multi-class problems such as identifications of sub-
types of same cancer.  
In contrast,  unsupervised learning methods involve information of samples,  
genes or both into different clusters consist of similarities in gene expression 
values (Eisen et al., 1998). The fundamental goal of clustering is to divide 
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objected into groups with similar characteristics. Several clustering has been 
applied to microarray data analysis such as hierarchical clustering,  self-organising 
maps,  and K-means clustering (Quackenbush, 2001). The advantage of 
unsupervised learning is that this is method is unbiased and allows significant 
discoveries in complex data sets without any background information about the 
structure.  
1.3 DNA Microarray and its Role in Cancer Research 
DNA microarray technology has been extensively used in cancer research for the 
past numbers of years now,  specifically in search of gene expression signatures 
for the prediction of diagnostics and prognostics categories of cancer patients 
(Sørlie et al., 2001, Golub et al., 1999).  
1.3.1 Diagnostics Classification 
One of the most prevalent and challenging problem in cancer research is the 
histopathological identification and classification of various cancers. Similar 
morphological cancers may belong to distinct clinical subtypes despite the same 
origin. The ability to identify unknown cancer samples into particular subclasses 
may provide an edge for more efficient cancer diagnosis.  
The earliest study by Golub et al. (Golub et al., 1999) exploited the gene 
expression profiling technique for cancer diagnosis of 6, 817 genes in 72 human 
acute leukaemia tumour samples. They used unsupervised learning method and 
suggested two major clusters of leukaemia subtypes, acute myeloid leukaemia 
(AML) and lymphoblastic leukaemia (ALL). Followed by the clustering into 
subtypes, a weight gene classifier was build using supervised learning method for 
the classification of unknown samples into the correct class of AML and ALL. 
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The accuracy of the classifier was assessed using cross-validation on training set 
as well tested on the independent set of samples.  
A number of other studies have also used gene expression profiling techniques for 
the classification of various cancers (Bittner et al., 2000, Welsh et al., 2001, Perou 
et al., 2000, Bhattacharjee et al., 2001). Adding to that,  diagnostics classification 
studies have been performed on number of different cancers such as,  prostate 
cancer (Singh et al., 2002),  lung cancer (Bhattacharjee et al., 2001),  breast cancer 
(Perou et al., 2000),  bladder cancer (Dyrskjøt et al., 2003),  head and neck cancer 
(Belbin et al., 2002) and ovarian cancer (Ono et al., 2000). For the classification 
of multiple types of cancers,  several techniques of multiple tumour classifiers 
have been proposed by exploring the microarray gene expression data to 
discriminate different kind of cancer types based on their tissues of origin (Su et 
al., 2001, Ramaswamy et al., 2001). These methods includes classification tree 
(Giordano et al., 2001),  linear discriminatory analysis (LDA) (Shen et al., 2006),  
artificial neural network (ANN) (Bicciato et al., 2003),  nearest neighbour 
classifier (Li et al., 2001),  and support vector machine (Liu et al., 2005). 
Support vector machine is the most popular classifier applied in microarray data 
analysis of different cancers. The first application of support vector machine was 
achieved by Mukherjee et al. (Mukherjee et al., 1999) followed by the wide 
spread use in molecular classification of microarray expression data. Support 
vector machines classifier were largely designed for two binary classifications but 
can be customised for multiple tumour types.  
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1.3.2 Prognostic Classification  
One of the most intriguing and contributing applications of DNA microarrays in 
cancer research is the estimation of clinical outcome based on gene expression 
profiles. Unlike molecular diagnostics predication, clinical outcome prediction is 
not just dependent on gene expression profiles but mainly deals with a correlation 
of gene expression profiles and clinical outcome.  
The earliest study conducted by Alizadeh et al. (Alizadeh et al., 2000) in diffused 
B-cell lymphoma (DLBCL) samples,  and predicted the correlation between gene 
expression profiles and clinical outcome. This study uses unsupervised learning 
method on B-cell malignancies and identified two molecular forms of DLBCL 
which indicate different stages of B-cell. This study on DLBCL has led the 
identification of previously undetected subtypes.  
Another major focus of DNA microarray was a prognostic classification of Breast 
cancer. Studying lymph-node status at the time of diagnosis is one of the best 
indicators of future relapse and survival outcome of breast cancer patients. Earliest 
studies have also indicated that the systematic adjuvant chemotherapy reduces the 
risk of metastasis and also survive breast cancer long (Cole et al., 2001). A 
pioneering study in clinical outcome prediction was conducted by can't Veer et al. 
(van 't Veer et al., 2002),  applied microarray data analysis to primary tumours of 
117 patients samples of lymph-node-negative and identified 70-gene prognostic 
signature predictive of clinical outcome. The prognostics signature was further 
validated on independent data set of 295 patients samples with best discriminatory 
power currently observed in the breast cancer clinical prediction.  
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The successful validation of 70-gene prognostic signature has led the discovery of 
many other prognostic signatures of breast cancer (Naderi et al., 2007, Wang et 
al., 2005b, Sotiriou et al., 2006). Similarly outcome prediction based on gene 
expression profiles was expanded to many other cancer types such as,  lung cancer 
(Beer et al., 2002),  prostate cancer (Singh et al., 2002),  brain cancer (Pomeroy et 
al., 2002),  and renal cancer (Takahashi et al., 2001). Studies such as above 
highlights the great potential for gene expression profiling in the identification of 
prognostic signatures for predicting clinical outcome. However further validation 
of this gene signature is required.  
1.4 Microarray Data Integration  
Recent studies highlighted the discovery of DNA microarray provided powerful 
tools which accomplished meaningful insights in cancer research. Similarly other 
studies have also utilised this technology to identify vital gene signature that can 
discriminate between the diagnostic categories along with the prognosis of cancer 
patients (Sotiriou et al., 2006, Bittner et al., 2000, Sørlie et al., 2001, Eisen et al., 
1998, Golub et al., 1999, van 't Veer et al., 2002). However, microarray 
characteristic of high noise, cost and small patient samples size of individual study 
makes it difficult to identify reliable gene signature for diagnostics.  
Another interesting but anticipated evidence is that only a small overlap between 
the gene signatures have been observed from the studies of a different investigator 
of same cancer type, may be due to protocol differences. A recent study by Ein-
Dor et al. (Ein-Dor et al., 2005) question this disagreement on signature 
uniqueness is not just because of different platform,  sample scarcity and 
experiment protocol,  but the signature prediction is strongly influenced by a 
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subset of the patients used for the signature identification. Hence, the signature 
difference might be largely contributed by sample size in individual studies and 
suggested large sample cohort will produce more robust signatures.  
Considering the cost of performing DNA microarray analysis and scarcity of 
certain tumour samples such in our case (colon cancer), it is very difficult to 
performed large scale analysis. In addition to that, it is very hard to repeat 
expression reading from the valuable specimens. Therefore, accumulation of gene 
expression data achieved from various investigators, generated in different 
laboratories may address the question surrounding small sample size. Another 
advantage of this microarray data integration would be to identify gene features 
which might be covered by small samples size and experimental protocol. 
Successful integration might lead to the discovery of robust and accurate gene 
signature important for diagnostics classification and improve statistical 
correlation with clinical outcome. 
1.4.1 Types of Microarray Data Integration  
The rapid increase in microarray data has offered researcher to proposed novel 
integration methods which can effectively accumulate data generated by various 
investigators and from different laboratories. In principle, integration of multiple 
microarray platform data should produce more reliable results since the analyses 
are performed on large samples size and individual study biased is also reduced. 
Several methods have been proposed for inter-study microarray data integration at 
the different level of studies. But these methods can be divided into two major 
categories considering their level of integration: meta-analysis, which combined 
the results after the class comparison (e.g. t-test statistics) from individual data 
sets which also avoid direct comparison of expression matrixes, and direct 
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integration of individual expression data matrixes after performing quality control 
tests such as transformation and normalization. 
1.4.2 Problems in Data Integration 
In ideal condition, any gene expression experimental data obtained from any 
research laboratory, using any protocol, at any time, using microarray technology 
platform, should be comparable. However, this is unachievable in reality and often 
poses massive challenges due to lack of uniformity in standards to microarray data 
integration. Numerous problems have been identified when attempting to integrate 
microarray data generated by individual studies groups using multiple array 
platforms. 
Till now, several studies have shown that gene expression level measurements 
from different microarray platforms, such as spotted cDNA and oligonucleotide 
arrays, might have poor correlation and direct comparison might be meaningful 
(Tan et al., 2003, Mah et al., 2004, Kuo et al., 2002). The identifying divergence 
among the different arrays may be due to the differences in probe set used, 
platforms technologies, labelling and hybridizing protocols, as well as differences 
in data extraction techniques such as background correction, normalization, and 
calculation of expression values. Such as, the data obtained from cDNA 
microarray is usually defined by the ratio between the diseases (experimental) and 
the control expression values which cannot be directly compared with the 
oligonucleotide microarray data which is defined as expression values of disease 
samples.  
Along with the observed difference between the various microarrays platforms,  
comparison between the microarrays data obtained from multiple-laboratories 
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have demonstrated major differences in data from individual studies extracted 
using the same microarray platforms than that obtained in the same lab using 
different microarray platforms (Nimgaonkar et al., 2003, Wang et al., 2005a). This 
particular issue also suggests that data obtained from different laboratories could 
not be compared even though the data was extracted using same microarray 
platform.  
Another issue linked to microarrays is a broad lack of reproducibility among the 
generations. Commercially produced microarrays such as Affymetrix have several 
generations of microarrays in order to compete with the advances in gene 
sequencing. So any new discoveries related to novel genes and their representative 
composition is frequently shared and updated with new developments microarrays 
using the field of biotechnology. Consequently, any probe set data consisting of 
newly discovered genes are incorporated into new generations of commercially 
available microarrays and the existing probe sets are modified for better detection 
targeted gene sequences. A recently conducted study has highlighted the issue of 
reproducibility among the two different generations by analysing the 
reproducibility factor. They identify the Affymetrix are high reproducible with in 
one generation but reproducibility across the two different generation depend up 
on the degree of similarity among the probe sets and the expression levels 
(Nimgaonkar et al., 2003). This issues suggest even using the same microarray 
platform but having different generations would make direct integration difficult 
due miss-matching in the probe sets and duplicated spots. 
In addition to above-discussed issues, there is multiple factors which could make 
the direction comparison very difficult. Such as, variation among the data sets, the 
difference resulting from the technical variability, the difference in sample size, 
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preparation methods and experiments controls, array quality, RNA detecting 
methods and RNA quality further deepens the challenges to integrating data from 
individual’s studies. 
1.5 Thesis Overview 
The aim of this study is to performed microarray integrated analysis on high-
throughput colon cancer data for the prediction of novel diagnostic and prognostic 
signature identification. 
The main objective of this thesis was to propose novel diagnostic and prognostic 
signature gene which can address the issue of heterogeneity and accurately predict 
the clinical outcomes of patients when tested on the wider population. As we 
highlighted earlier that many attempts have been made for the prediction of colon 
cancer signatures that can precisely separate colon cancer from others and 
accurately predict the outcome in clinical practices. Chapter 3 presents the first 
independently study where we implemented tissue-based integration analysis and 
identified novel diagnostic and prognostic signatures by establishing workflow 
Independent of microarray data limitation of sample size, platform and other 
experimental protocols. We searched the PubMed database for the latest 
development in colon cancers applying the microarray tools and selected the high-
quality studies. We performed the tissue-based comparison for the selection of 
differentially expressed genes and the searched for the overlapping genes in all the 
comparison. We tested the diagnostic signature proposed from the normal versus 
primary colon comparison on cross-validation loop for their ability to discriminate 
colon tumours from normal colon among all the cohort data sets. We also tested 
prognostic signature generated from the comparison of normal versus metastatic 
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and primary colon versus metastatic colon using univariate cox proportional 
hazard analysis. 
In the second independent study, we performed integration analysis of two 
different data levels for the identification of factors which contribute the 
heterogeneity of colon cancers and for the identification of functional genes 
involved in the metastases of colon cancer. As we know, in order to understand 
the genetic basis of complex traits such as colon cancer has been a challenge for 
past few years now. But with the increase in expression data and advances in 
technology from multiple levels of biological systems has been a game changer. 
Various analytical approaches have been developed to identify the genetic 
variation that underlies complex traits. Such as variation in gene expression (using 
microarrays and RNA sequencing (RNA-seq)), epigenetic variation (by 
microRNAs, methylation arrays, methylation sequencing or chromatin 
immunoprecipitation followed by sequencing (ChIP–seq)) and protein variation. 
Therefore, in this study, we identified microRNA signature that can differentiate 
primary and metastatic tumours, its stages and tumour grades in patients with 
colorectal carcinoma. In an integrative model, we performed differential 
expression analysis between histopathological groups and identified significantly 
dysregulated miRNAs followed by the target prediction analysis to establish their 
tumour transcriptional phonotypes. Furthermore, we focused on the identification 
and evaluation of miRNAs potentially involved in prognosis and functional 
processes during metastatic progression. 
 
  
14 | P a g e  
 
CHAPTER 2 LITERATURE REVIEW  
2.1 Background of Colon Cancer 
Numerous of studies have confirmed the use of microarray data analysis role of 
expression profiling in the identification of novel diagnostic markers, drug targets 
for personalised medicine and tumour classifications into subtypes. In 2002, the 
earliest effort of an integrated analysis of data consisting of gene expression 
profiling and drug sensitivity have been used in the assessment of clinical tumours 
for the prediction of biomarkers that can predict therapeutic efficacy (Orr and 
Scherf, 2002). This technique of gene-drug correlation had been employed for 
selecting therapeutic options for tumours on the basis of their molecular 
characteristics. The main focus of this technique was sensitivity rather than 
actually focusing on molecular significances of therapy. Therefore, the earliest use 
of gene expression data in correlation with drug sensitivity database was a 
proposal of antimetabolite 5-FU gene-drug correlation, which was used for the 
treatment of breast and colon cancers by inhibiting both RNA processing and 
thymidylate synthesis. 
Another way of studying the development of any type of a tumour is by closely 
analysing the sequence of events. Studying this general model for colon cancers 
and all those sequences that lead formation of adenoma to carcinoma usually 
occur through genetic and epigenetic changes (Fearon, 2011). Similarly, various 
molecular phenotypes have been used to classify the colon cancers in the past 
(Sanchez et al., 2009). Such as phenotype based on microsatellite instability (MSI) 
(Iacopetta et al., 2010), phenotypes based on epigenetic changes were studying of 
methylation state of CpG islands (van Engeland et al., 2011), phenotypes based on 
the genetic aberrations were presence of genes such as KRAS or BRAF, and 
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phenotypes based on functional pathways were presence of Wnt/ß-catenin, TGF-
ß, MAPK, and PI3K signaling (Fearon, 2011). 
In the past, molecular studies mainly focused on individual gene targets rather 
than addressing the molecular heterogeneity of the disease. The introduction of 
DNA microarray technology offered an investigation of thousands of genes at the 
mRNA expression levels. Therefore, provided an alternate to single gene 
discovery to thousands of genes simultaneously in a single assay, thus offered 
solutions to address the problem of heterogeneity of complex diseases (Mohr et 
al., 2002, Bertucci et al., 2001).  Number of earlier publications based on gene 
expression profiling of colon cancers have performed comparison of normal 
versus tumour tissue samples or comparison among the histological stages (Alon 
et al., 1999, Backert et al., 1999, Hegde et al., 2001, Kitahara et al., 2001, 
Notterman et al., 2001, Agrawal et al., 2002, Birkenkamp-Demtroder et al., 2002a, 
Lin et al., 2002, Zou et al., 2002, Frederiksen et al., 2003b, Tureci et al., 2003, 
Williams et al., 2003) but none of them focused on the disease prognosis and MSI 
phenotype. Bertucci and colleagues (Bertucci et al., 0000) have used application 
of DNA microarray data analysis on 8,000 genes of 50 colon cancer tissues and 
identified several dysregulated genes among the normal and cancer samples along 
with the prediction of clinical outcomes and MSI phenotype. 
Molecular level similarities are essential in the identification of specific pathways 
affected in diseases, in the identification drug targets or achievement and 
designing of survival outcome classifiers.  
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In 1932 the British pathologist Cuthbert Dukes devised a classification system for 
colon cancer. Several different forms of the dukes’ classification were developed. 
Such as: 
Dukes'A: The cancer is in the inner linning of the bowel, it is slightly 
growing into the muscle layer.  
Dukas's: cancer has grown through the muscle layer of the bowel. 
Dukes’C: cancer has spread to at least 1 lymph node close to the bowel. 
Dukes’D: cancer has spread to another part of the body, such as liver, 
lungs or bones 
 
Previously, several attempts have been made to subdivide colon tumours into 
further sub-classes or to correlate gene expression with Dukes stages hasn’t been 
fruitful. Some of them successfully classify normal colon, Duke B and C but not 
Duke A and D (Frederiksen et al., 2003a), one of them has been able to classify 
Duke A in normal colon but not B, C and D (Birkenkamp-Demtroder et al., 
2002b). Other authors were unable to find the difference between stages of colon 
A, B and C (Kwong et al., 2005). Perez Villamil et al. proposed a novel method 
aiming to obtain more homogeneous groups of colon tumours for the discovery of 
molecular uniform subgroups that are more likely to discriminate patient with 
different clinical outcomes along with the better understanding of biological 
pathways forming different tumour subtypes (Perez Villamil et al., 2012a).    
In another study conducted by a group of Cancer Genome Atlas performed 
genome-scale analysis of 276 patients suffering from colon cancers (The Cancer 
Genome Atlas, 2012). In this multidimensional approach, the investigators divided 
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colon data into those with microsatellite instability (MSI) and those that are 
microsatellite-stable (MSS). In results, they observed a number of important genes 
and critical pathways required for the initiation and progression of colon cancers. 
Some of the significant findings from this study were the discovery of P53, PI3K, 
RAS-MAPK, TGF-β, WNT, and DNA mismatch repair pathways. In spite of such 
progress, there are still some unknown genetic and genomic changes which play a 
significant role in colon tumorigenesis. 
Gene expression profiling-based on colon cancers have been poor in terms of 
reproducibility largely due to involvement complex pathways and heterogeneity 
with in disease (Kang, 2011, Jass, 2007). As a result, several diagnostic and 
prognostic signatures have been proposed addressing the distinct gene features 
and pathways. Recently, gene expression profiling-based studies have integrated 
genetic and epigenetic analysis has identified three distinct molecular subtypes of 
colon cancers (2012, Jass, 2007, Salazar et al., 2011). Hence colon cancer should 
not be considered as one disease but a collection of sub-entities. However, there is 
urgent need of redefining molecular classification currently based on biomarkers 
such as MSI, CpG island methylator phenotype CIMP, chromosomal instability 
CIN, and BRAF and KRAS mutations (Shen et al., 2007, Kang, 2011).  
2.2 Review of Microarray Data Integration 
The fast pace increase in microarray data has forced the researcher to create and 
build effective methods to integrate data produced from disparate laboratories 
using different microarray technology platforms. There is a strong agreement in 
the integrating multiple data sets to produce more reliable and strictly valid 
results. This is largely due to the reasons that yield analyses are performed using a 
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larger number of samples and the effects of individual study-specific biases are 
reduced. Consequently, a number of methods have been introduced to integrated 
inter-study microarray data at different levels in microarrays (Warnat et al., 2005, 
Ghosh et al., 2003, Ramaswamy et al., 2003). These integration methods broadly 
fall into two categories: a meta-analysis, which combines the results (t-test 
statistics) from individual studies just to avoid the direct comparisons of 
expression values, and direct integration of expression values after some 
transformation methods such as normalization etc.  
Several studies have adopted this method of combining results of individual 
studies to increase the power of identifying significantly expressed genes across 
studies instead of integrating microarray gene expression values (Zhou et al., 
2005, Stevens and Doerge, 2005, Ghosh et al., 2003, Ramaswamy et al., 2003, 
Nimgaonkar et al., 2003).  One of the earliest efforts by Rhodes et al. (Rhodes et 
al., 2002) in which they exploited the meta-analysis method and proposed a 
statistical model for integrating four independent microarray data sets from two 
different microarray platforms, spotted cDNA arrays and Affymetrix arrays, 
respectively. Each of the identified gene in each study was treated as an 
independent hypothesis and significance value (p-value/q-value) was allocated to 
each gene in each study based on random permutations. Following to above step, 
the similarity of significance across studies was evaluated with meta-analysis 
methods combined with multiple inference statistical test for each possible 
combination of studies. Another study based on significantly dysregulated in 
prostate cancer; Choi et al. (Choi et al., 2003) proposed a new meta-analysis 
method,  which combines the results from an individual study in the form of effect 
size and has the ability to model the inter-study variation. The effect size was 
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calculated mean difference between cancer and normal samples in a microarray 
data set. Afterword, the author combined the individual study effect sizes from 
multiple microarray data sets to estimate the overall mean following by 
calculation of statistical significance using permutation test extended to multiple 
data sets. They successfully established that combining data using this method 
supported the discovery of small but consistent expression changes and may 
increase the sensitivity and reliability of analysis. Hu et al. (Hu et al., 2005) 
proposed an extended version of effect size model for the meta-analysis of 
microarray data.  
Multiple studies have reported success using meta-data analysis method for 
integration individual microarray studies but small sample size, coupling with 
divergences due to the difference in studies protocols have affected the final 
results of meta-analysis method. This is the main weakness of using this method 
reported till now. In addition to this, recently studies also highlighted that there is 
moderate overlap between the gene signature detected using individual studies 
using different platforms. So there are strong chances of losing important genes 
using this meta-analysis method (Mah et al., 2004).  
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CHAPTER 3 INTEGRATED ANALYSIS OF GENE EXPRESSION DATA 
FOR COLON CANCER BIOMARKER DISCOVERY 
3.1 Introduction 
Colon Cancer (CC) is a common malignancy affecting both women and men. 
Despite recent advances in the screening, diagnosis, and treatment of colorectal 
cancer, an estimated 608, 000 people die every year from this form of cancer. 
Pathological staging is the only prognostic classification used in clinical practice 
to select patients for adjuvant chemotherapy. However, pathological staging fails 
to predict recurrence accurately in many patients undergoing curative surgery for 
localized CRC. In fact,  10%-20% of patients with stage II CRC,  and 30% - 40% 
of those with stage III CRC  develop recurrence (Zhang et al., 2001).  
Among the molecular markers that have been extensively investigated for colon 
cancer (CC) characterization and prognosis. DNA mismatch repair (MMR) 
system,  is the only marker that was reproducibly found to be a significant 
prognostic factor in early CRC in both a meta-analysis and a prospective 
trial (Nannini et al., 2009, Zhang et al., 2001). Precise classification of the tumor 
is critically important for cancer diagnosis and treatment. During the past decade,  
efforts have been made to use gene expression profiles to improve the precision of 
classification,  with limited success (Cardoso et al., 2007). Many studies have 
exploited the use of microarray technology to investigate gene expression profiles 
(GEPs) for the diagnosis of colon cancer in recent years,  but no signature has 
been to be useful for clinical practice,  especially for predicting 
prognosis (Sagynaliev et al., 2005). It is shown that the reproducibility of GEP 
studies on colon cancer has not been sufficient for clinic practice,  possibly 
because colon cancer cells are composed of distinct molecular entities that may 
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develop through multiple pathways (Chan et al., 2008, Shih et al., 2005). 
Therefore, there may be several prognostic signatures for CRC, each 
corresponding to a different entity.  
Indeed, GEP studies, based on integrated analysis of genetic/epigenetic data 
including high-throughput methylene data (Nannini et al., 2009), have identified 
at least three distinct molecular subtypes of colon cancer. Therefore, colon cancer 
should no longer be considered as a homogeneous entity. However, the molecular 
classification of CC currently used, which is based on a few common DNA 
markers (MSI,  CpG island methylator phenotype [CIMP],  chromosomal 
instability [CIN],  and BRAF and KRAS mutations) (Kang, 2011, Jass, 2007),  
needs to be refined,  and a standard and reproducible molecular classification is 
still not available.  
In order for identifying more robust diagnostic gene signature of colon cancer, this 
Research thesis presents an investigated analysis of multiple latest competitive 
studies of various stages of colon cancer. We applied tissue-based differential 
expression followed by supervised machine learning approach for the discovery of 
diagnostic/prognostic gene signatures for the earlier and outcome identification of 
patients with colon cancers. We identified a 124-gene signature that can 
discriminate between the patients with good and poor outcomes, also provide 
evidence of functionally involved in immune response, lipid metabolism and 
PPAR signalling pathways.  
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Table 1. A summary cohort of studies involving Colon cancer. 
Author Studies Cohort Sample Size Platform Dataset 
Musella et al. 
(2013) 
Time course analysis 
of colon cancer 
samples 
Normal vs 
Tumor 
N=88,  T=84 
GPL6947 
Illumina 
HumanHT-12 
V3.0 expression 
bead chip 
GSE37182 
Shaffer et al. 
(2009) 
Expression data from 
colorectal cancer 
patients 
Normal vs 
Tumor vs Mets 
N=54,  
T=186,  
M=67 
Affymetrix 
Human 
Genome 
U133A Array 
GSE41258 
Agesen et al. 
(2013) 
Specific extracellular 
matrix remodelling 
signature of colon 
hepatic metastases 
Normal vs 
Tumor vs Mets 
N=18,  
T=20,  
M=19 
Affymetrix 
Human 
Genome 
U133A Array 
GSE49355 
This table is just showing the numbers of studies included in our analysis cohort. 
It can clearly be identified from the table that data sets were derived from different 
platforms of microarray studies. The first study comparing the normal versus 
tumour samples, and the other two studies comparison include expression from 
three different tissues including normal, primary and Mets. The dataset column 
includes the accession numbers of GEO expression data sets and general from 
starts from GSE followed by identification number.  
3.2 Method 
We performed two staged integrated analyses on the expression data sets on three 
lately developed studies based on gene expression analysis of colon cancer for the 
discovery of potential gene signature. In order to extract the biological 
information, we further performed gene ontology enrichment analysis in order to 
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identify the functional pathways involved in localised colon cancer as well as 
spread to other tissues. We searched studies involving applications of gene 
expression profiling on patients involving samples primary and metastatic tumour 
tissues. 
3.2.1 Data Collection 
The three microarray expression data sets were obtained using GEO query 
Bioconductor R package (Davis, 2013) from the Gene Expression Omnibus 
(GEO) database (http://www.ncbi.nlm.nih.gov/geo) (Table I). The expression data 
sets involve samples from normal, primary tumour and metastatic tissue samples. 
In order to identify tissue specific mRNA signatures, we performed comparisons 
of among three tissues to identify specific dysregulated mRNAs. 
3.2.2 Statistical Analysis 
Each of the extracted raw expression data sets was log-transformed and 
normalised by quantile method individually. Using R/Bioconductor, linear models 
for microarray data analysis were employed by forming contrast matrix 
comparisons for normal vs a primary tumour, normal vs Mets and primary tumour 
vs Mets. Significance value (P-Value < 0.05) and log scale (log FC > 1 | log FC < 
-1) was used to rank the genes of interest. Corrections for multiple comparisons 
were done using false discovery rate (FDR) method. NCBI’s original genome 
annotation was used to obtain gene symbols for probe sets id’s.  
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Venn diagram showing the common and unique genes of resulted gene lists after 
comparison between normal versus tumour samples. We found 267 genes 
signatures which are common in all three comparisons. Following the 
identification of dysregulated gene lists from the comparison of normal versus 
primary tumour tissues classes of each eligible study, we combined the resulted 
gene lists to form an inter-study signature gene set. In this case, we observed 267 
genes were common to three gene lists of normal versus primary tumour 
comparison of three investigated data sets. 
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Venn showing normal versus Mets comparison 
 
We focused our attention towards comparison of differentially expressed profiles 
among a tumour versus Mets tissues comparison and identified 124 genes were 
common between the resulted gene lists. We observed a number of notable genes 
were previously linked with metastases in colon cancer.  
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We further analysed identified signatures by performing meta-analysis among 
inter-study signature derived from individual comparisons of normal versus a 
tumour, normal versus Mets and tumour versus Mets tissues by comparing the 
similarities between them. We observed overlapping of 184 genes between normal 
versus a tumour and normal versus Mets gene lists. However, 64 genes of normal 
versus tumour comparison represents a strict tumour-specific (those genes which 
are not significantly dysregulated in another comparison) pool for which the 
functional analysis identified their targeted pathways involved.
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3.2.3 Functional Analysis 
We applied gene ontology enrichment analysis for the interpretation of gene 
signatures in order to identify potential biological processes, functional network 
and pathways. For this purpose,  we applied Functional Annotation Tool of 
DAVID Bioinformatics Resources 6.7 (Huang et al., 2009b) using default settings. 
We used gene symbols as input gene list for each derived signature by selecting 
the Homo sapiens as their population background. We used P-value < 0.05 as a 
cut-off value for the selection of DAVID terms and this reason for choosing this 
criterion so that its conclusions to be drawn about the statistical plausibility and 
clinical relevance of the study findings.  
3.2.4 Classification Performance Evaluation 
We applied supervised machine learning approach in order to study the reliability 
and robustness of inter-study signature. We estimated classification performance 
on each expression data sets by building a classifier using signature genes,  as a 
feature vector,  and their corresponding expression data from (Musella et al. 
(2013),  Shaffer et al. (2009),  Agesen et al. (2013)) using the cross-validation 
loop on support vector machine (SVM) (Mukherjee et al., 1999). We used 
standard leave one-out cross-validation (LOOCV) to estimate the accuracy of 
above classifier. Hence, for every sample xn in the training set S, we train the 
classifier by leaving one sample (N-1) and then classifying the left out sample to 
predict the label of xn.  
3.2.5 Survival Analysis 
We performed prognostics analysis for the 124-genes signature derived from the 
comparison of a tumour versus Mets tissues. For this purpose, we used 
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independent data set (GSE17538) from the study conducted by Smith et al. (Smith 
et al., 2010) derived from metastatic colon cancer. We tested 124-genes 
association with the clinical endpoints such as Overall survival (OS), Disease-
specific survival (DSS) and Disease-free survival (DFS) across all the grades 
(grade 1, 2 and 3) by building Cox proportional hazard (PH) model. We build 
classifiers using genes from signature genes and their corresponding values from 
the training set for the calculation of Wald score for each of the genes in the 
classifier. Log-rank tests P-Value were computed for both univariate and 
multivariate Cox model for OS, DSS and DFS. Similarly, Kaplan-Meier estimates 
were calculated for each endpoint. 
3.2.6 Validations  
For the validation of these studying findings, we applied two approaches: first we 
validated our proposed signature using in-silico cross validation and second 
approach we applied to the literature search of signature genes from previously 
published studies and curated cancer signature databases. Therefore, we searched 
gene signature database GeneSigDB (http://compbio.dfci.harvard.edu/) for the 
potential overlaps between the proposed signatures and previously published 
signatures.  
3.3 Results 
3.3.1 Gene Expression Analysis and Microarray Data Integration  
We performed differential expression analysis on each of the studies by 
comparing expression profiles of normal, tumour and metastatic tissues samples. 
We employed t-test statistics among the contrast matrix comparisons for the 
identification of dysregulated genes. 
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3.3.2 Expression in Normal and Primary Tumour Colon Tissues 
To investigate the difference in human colon cancer, we performed differential 
expression using normal versus tumour samples of each data set. We identified 
2358 dysregulated (2144 up-regulated and 214 down-regulated) genes consisting 
of 88 normal and 84 primary tumour samples of Musella et al. study. Similarly, 
we observed 2696 genes (724 up-regulated and 1972 down-regulated) and 1050 
genes (366 up-regulated and 684 down-regulated) from Agesen et al. and Shaffer 
et al. studies, respectively. We excluded all those probes set ids with no gene 
symbols for further analysis.  
Following the identification of dysregulated gene lists from the comparison of 
normal versus primary tumour tissues classes of each eligible study, we combined 
the resulted gene lists to form an inter-study signature gene set. In this case, we 
observed 267 genes were common to three gene lists of normal versus primary 
tumour comparison of three investigated data sets (Figure 1). 
The gene ontology functional analysis of 267-genes shows over-representation of 
signalling-related molecules in processes and networks (Fig 2). We also identified 
pathways significantly (P-value < 0.05) involved in various cancers such as 
bladder cancer and acute myeloid leukaemia. Known signalling and metabolic 
pathways also featured among the top ten regulatory identified pathways (Table 
2).
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Figure 1. Top-ten processes and molecular functions. 
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Table 2. Top 10 functional regulatory pathways. 
Pathways P-Value Genes 
Focal adhesion 6.82E-05 
CAV1,  MET,  FLNC,  COL5A2,  COL5A1,  
PRKCB,  MYL9,  CCND1,  VEGFA,  COL1A2,  
COL1A1,  COL11A1,  THBS2,  MYLK,  SPP1 
ECM-receptor interaction 8.12E-03 
COL1A2,  COL1A1,  COL5A2,  THBS2,  
COL11A1,  COL5A1,  SPP1 
Bladder cancer 1.12E-02 CCND1, MMP9, VEGFA, MYC, MMP1 
Nitrogen metabolism 1.18E-02 CA7, CA4, CA2, CA1 
Complement and coagulation 
cascades 
1.45E-02 C7, F12, CFB, SERPINE1, CFD, PLAU 
Cell cycle 1.57E-02 
CDK1, CCND1, E2F5, BUB1, MCM4, MYC, 
CDC25A, CDC25B 
Vascular smooth muscle 
contraction 
2.99E-02 
KCNMA1, ACTG2, MYH11, KCNMB1, 
MYLK, PRKCB, MYL9 
Acute myeloid leukemia 3.30E-02 CCND1, LEF1, ZBTB16, RUNX1, MYC 
Leukocyte transendothelial 
migration 
3.73E-02 
CLDN8, MMP9, CLDN1, CXCL12, PRKCB, 
THY1, MYL9 
Wnt signaling pathway 3.90E-02 
WNT5A, CCND1, SFRP1, MMP7, CHP2, 
LEF1, MYC, PRKCB 
 
In table 2 we identified pathways significantly (P-value < 0.05) involved in 
various cancers such as bladder cancer and acute myeloid leukaemia. Known 
signalling and metabolic pathways also featured among the top ten regulatory 
identified.
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In the second step of bioinformatics analytics, we investigated reliability and 
robustness of proposed 264-gene signature using each of the expression data sets 
generated from different platforms (Table 3). The 264-gene signature consistently 
achieved high classification accuracy ratios across all the data sets, classifying 
with 100%, 93.84% and 77.77 %, respectively.  
Table 3. Leave one out cross-validation classification of normal versus tumour signature (264-
genes). 
Author Expression Set 
No. of 
Samples 
Accuracy (%) Sensitivity (%) 
Specificity 
(%) 
Musella et al. (2013) GSE37182 N=88, T=84 100 100 100 
Shaffer et al. (2009) GSE41258 
N=54, T=186, 
M=67 
93.84 92.82 100 
Agesen et al. (2013) GSE49355 
N=18, T=20, 
M=19 
77.77 81.7 96.6 
We investigated reliability and robustness of proposed 264-gene signature using 
each of the expression data sets generated from different platforms. 
3.3.3 Expression in Metastasis Tissues 
Similarly, we carried out differential expression analysis for a subset of Shaffer et 
al. data set consist of 54 normal and 67 Mets samples and identified 1328 genes 
were significantly dysregulated. Among the total identified 1328 genes, 1310 have 
shown over-expression whereas 18 genes were under-expressed.  
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Table 4. Leave one out cross-validation classification of normal versus Mets signature (877-
genes). 
Author Expression Set 
No. of 
Samples 
Accuracy (%) Sensitivity (%) Specificity (%) 
Musella et al. 
(2013) 
GSE37182 
N=88, 
T=84 
100 100 100 
Shaffer et al. (2009) GSE41258 
N=54, T=186, 
M=67 
93.39 96.82 100 
Agesen et al. (2013) GSE49355 
N=18, T=20, 
M=19 
93.33 93.17 96.6 
Likewise, analysis using a subset of Musella et al. study consists of 18 normal and 
19 metastatic samples have shown deregulation of 3122 genes, mostly 3098 
showing over-expression (log FC > 1). We also focused our attention towards 
comparison of differentially expressed profiles among a tumour versus Mets 
tissues comparison and identified 124 genes were common between the resulted 
gene lists. We observed a number of notable genes were previously linked with 
metastases in colon cancer.  
Table 5. Leave one out cross-validation classification of a tumour versus Mets signature (124-
genes). 
Author Expression Set 
No. of 
Samples 
Accuracy (%) Sensitivity (%) Specificity (%) 
Musella et al. 
(2013) 
GSE37182 
N=88,  
T=84 
100 100 100 
Shaffer et al. (2009) GSE41258 
N=54, T=186, 
M=67 
72.96 72.82 95.53 
Agesen et al. (2013) GSE49355 
N=18, T=20, 
M=19 
76.86 80.39 96.6 
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3.3.4 124-gene metastatic signature identified patients associated with poor 
outcome in independent data set 
An independent human colon cancer gene expression and clinical data set was 
used to test the ability of 124-gene signature that discriminate between patient 
associated with cancer reoccurrence, overall survival and disease-specific 
survival. 238 patients with histopathological properties of age, gender, ethnicity, 
stage and grade were available for analysis. We observed, patients with higher 
grade (grade 3) across all the grades in independent set has significantly better OS 
(p=0.001, HR=2.61(CI 1.43-4.79); p=0.16, HR=1.42(CI 0.86-2.35), respectively) 
and DSS (p=0.00, HR=2.41(CI 1.28-4.53); p=0.25, HR=1.35(CI 0.80-2.28) 
compare to low grade patients. 
Similarly, we determine the relative risk of reoccurrence and cancer-related 
deaths. We observed a significant association of 124-gene signature with the risk 
of reoccurrence when analysed across all the tumour grades (p=0.0003, 
HR=1.74(CI 1.28-2.37)). We also analysed that the relative risk of reoccurrence 
has increased with the increase of tumour grade in patient samples (grade 3 
(p=0.0005, HR=2.94(CI 1.59-5.46))) (Figure 3).  
We performed prognostics analysis for the 124-genes signature derived from the 
comparison of tumour versus Mets tissues. For this purpose, we used independent 
data set (GSE17538) from the study conducted by Smith et al. (Smith et al., 2010) 
derived from metastatic colon cancer.  
We tested 124-genes association with the clinical endpoints such as Overall 
survival (OS), Disease-specific survival (DSS) and Disease-free survival (DFS) 
across all the grades (grade 1, 2 and 3) by building Cox proportional hazard (PH) 
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model. We build classifiers using genes from signature genes and their 
corresponding values from the training set for the calculation of Wald score for 
each of the genes in the classifier. Log-rank tests P-Value were computed for both 
univariate and multivariate Cox model for OS, DSS and DFS. Similarly, Kaplan-
Meier estimates were calculated for each endpoint. 
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Figure 2. The 124-gene classifier as tested in the independent data set across all grades. Kaplan–Meier estimates of overall and disease-specific survival in the 
test set. Expression data for probes corresponding to the 124-gene recurrence classifier were used to build the Cox proportional hazard model from patient data 
in the Vanderbilt dataset. Plots represent survival analyses in the independent patient data set (A) Overall survival, (B) disease-specific survival analyses and (C) 
disease-free survival 
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3.3.5 The Cancer-focused Genes  
We further analysed identified signatures by performing meta-analysis among 
inter-study signature derived from individual comparisons of normal versus 
tumour, normal versus Mets and tumour versus Mets tissues by comparing the 
similarities between them. We observed overlapping of 184 genes between normal 
versus tumour and normal versus Mets gene lists. However, 64 genes of normal 
versus tumour comparison represents a strict tumour-specific (those genes which 
are not significantly dysregulated in other comparison) pool for which the 
functional analysis identified their targeted pathways involved: cell cycle, acute 
myeloid leukemia, progesterone-mediated oocyte maturation, TGF-beta signaling 
pathway, role on ran in mitotic spindle regulation and G1-phase progression by 
my.  
Similarly, in normal versus Mets and tumour versus Mets, a total of 701 genes 
were differentially expressed among met tissues. We tracked the significant 
pathways involved: immune response, lipid metabolism and PPAR signalling 
pathway.  
3.4 Discussion  
The purpose of the present study to find possible marker gene sets for colorectal 
cancer by using a two-step bioinformatics analytics. We performed meta-analysis 
using publicly available GEO expression profiles of normal, tumour and 
metastatic tissues for the discovery of robust signature involving pathogenesis of 
colon cancer.  
We identified cross-study 267-gene signature from the comparison of normal 
versus primary tumour samples across all the data sets that may be vital for the 
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diagnosis of colon cancer. The functional analysis of 267-genes has revealed the 
involvement of cell cycle,  cell-signaling and metabolic regulated pathways as 
reported in the previous studies (Moreno and Sanz-Pamplona, 2015, Planutis et 
al., 2014). We further tested the robustness of gene signature using cross-
validation, which shows excellent 90.53% overall-average accuracy-rate across all 
the expression data sets. We also observed the Agesen et al. expression validated 
with higher error-rate compare too other two data sets in the validation cohort. A 
close examination of the cohort present possible to the explanation of these 
results; Agesen et al. study samples include stage IV tissues whereas Musella et 
al. and Shaffer et al. samples were derived from slightly earlier stages I-IV. 
However, we cannot rule out these variations are due to the difference in sample 
size and/or platform differences.  
For the Mets tissues analysis, we identified two gene sets of deregulated genes 
from the comparison of normal, tumour and mets tissues. Further analysis of 124-
genes deregulated among a tumour versus Mets tissues has shown involvement in 
key regulatory pathways such as complement cascade, the formation of the fibrin 
clot, extracellular matrix organization, collagen degradation and lipoprotein 
metabolism. Survival analysis of 124-gene signature using independent data sets 
has separated patients with high grades from lower grades when analysed for 
overall survival rate and disease-specific survival. The ability of 124-gene 
signature to discriminate between patient outcomes may be useful in patient 
prognosis, but further biological validation will be required. The prognostics 
results also show the positive correlation between the risk of reoccurrence and 
disease related deaths with the increase of tumour grade.    
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We also compared the similarities between the results of three signatures. The 
deregulated 64 genes were specific to normal versus primary tumour comparison 
have also shown significant linkages to cancer-related pathways. The other group 
of genes (701), strictly related to Mets tissues have also shown significantly 
involvement in pathways previously observed in colon cancer.  
In conclusion, this study shows the importance of integrated techniques of 
individually conducted gene expression studies and provide further insights into 
understanding of colon cancer data for clinical purposes. The cross-validation 
analysis of gene signature shows samples scarcity and different platform used for 
generation of expression remains challenging area. This study has also shown 
valuable knowledge and future direction for the treatment of colon cancers but a 
more robust approach using multiple biological stage data may answer a question 
related to molecular heterogeneity. 
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CHAPTER 4 GENOME-WIDE MICRORNA AND MRNA INTEGRATED 
ANALYSIS OF COLON CANCER 
4.1 Introduction 
The majority of deaths related to colon cancer are due to metastases in the primary 
tumour lesions,  and according to recent studies nearly half of the patients only 
survive for 5 years from the diagnosis of metastatic malignancy (Parkin et al., 
2005). Various studies have highlighted the first site on the onset of metastatic 
colon cancer is regional lymph nodes and then its spread to the liver. Pathological 
studies on colon cancer cannot precisely predict patients with metastatic 
vulnerability to local lymph nodes and/or to distant organs. 
The investigative studies on liver metastases have shown that it is often originated 
from colon cancers,  and there have been such practical evidence where metastasis 
reading is the first and only finding in patients with an unknown primary tumour 
site (Pavlidis et al., 2003),  and the discovery target sites can differentiate between 
primary hepatic lesions and liver metastasis from different possible origin sites 
can be therapeutic and prognostic value (Fernandez-Pineda et al., 2015). 
Therefore, there is an increasing urgency of novel diagnostic and prognostic 
biomarkers that could differentiate between the primary tumour and metastasis 
malignancies sites, as well as prediction of primary tumours having a tendency of 
metastasizing to other organs. Although, the association between colon cancer 
metastases and the mortality rate is very well studied the genomic mechanisms 
underlying tumour cell distribution and the primary tumour tendency for 
metastases is still poorly understood. However,  the discovery of new class RNAs 
(miRNAs) with the regulatory role may be integral in malignant processes (Su et 
al., 2010, Glud et al., 2010). 
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miRNAs (microRNAs), are small (19–25 nucleotides) on coding RNAs, that have 
the ability to regulate mRNA genes expression by suppressing mRNA translation 
during post translational modifications, and/or causing mRNA degradation. 
miRNAs are known to be involved in important regulatory processes by targeting 
translation sites of multiple mRNA genes (Bartel, 2004),  and are observed to 
expressed in tumour initiation and progression sites (Calin and Croce, 2006). c 
(Cho, 2007). The stimulating characteristics of miRNAs signatures being highly 
tissue-specific can be utilised to classify and investigate heterogeneous cancers 
and origin sites of colon metastases of unknown origin (Rosenfeld et al., 2008, 
Ramaswamy et al., 2001).  
 
The aim of our study was to identify a microRNA signature that can differentiate 
primary and metastatic tumours, its stages and tumour grades in patients with 
colorectal carcinoma. Furthermore, we focused on the identification and 
evaluation of miRNAs potentially involved in prognosis and functional processes 
during metastatic progression. For this purpose, we performed differential 
expression analysis between histopathological groups and identified significantly 
dysregulated miRNAs followed by the target prediction analysis to establish their 
tumour transcriptional phonotypes.    
4.2 Results  
4.2.1 Subtype-specific miRNAs 
In order to understand the impact of dysregulated miRNAs in the formation of a 
tumour transcriptional phenotypes, we investigated miRNA expression patterns 
across different histopathological tumour groups. We performed differential 
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expression analysis across tumour groups and identified approximately 70 highly 
dysregulated (p-value < 0.001) miRNAs (table 6).  
Table 6. Top differentially expressed miRNAs among histopathological groups.  
No. Differentially expressed miRNAs Gender Mets Grade Adjuvant chemotherapy Stages 
1 hsa-miR-378*-4373024 

   
2 hsa-miR-200c*-4395397 
   

3 hsa-miR-106b*-4395491 



 
4 hsa-let-7f-1*-4395528 
   

5 hsa-miR-15b*-4395284 



 
6 hsa-miR-424*-4395420 

 


7 hsa-miR-543-4395487 
   

8 hsa-miR-628-3p-4395545 
   

9 hsa-miR-769-5p-4395186 



 
10 hsa-miR-550-4395521 
 



11 hsa-miR-99b*-4395307 
   

12 hsa-miR-26b*-4395555 
   

13 hsa-miR-155-4395459 
 



14 hsa-miR-135a*-4395343 

 


15 hsa-miR-25-4373071 
   

16 hsa-miR-324-5p-4373052 
   

17 hsa-miR-27b-4373068 

 


18 hsa-miR-181c*-4395444 
   

19 hsa-miR-183*-4395381 
   

20 hsa-miR-335-4373045 

 


21 hsa-miR-26a-1*-4395554 

 


22 hsa-miR-143*-4395257 



 
23 hsa-miR-432-4373280 
  
 
24 hsa-miR-16-4373121 
   

25 hsa-miR-101-4395364 
   

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26 hsa-miR-505-4395200 
  


27 hsa-miR-938-4395292 
  


28 hsa-miR-193b-4395478 
  


29 hsa-miR-15a*-4395530 
  


30 hsa-miR-18a-4395533 
  


31 hsa-miR-526b*-4395494 
  


32 hsa-miR-376a-4373026 
  


33 hsa-miR-770-5p-4395189 
  


34 hsa-miR-10b-4395329 
  


35 hsa-miR-92a-4395169 
 

 
36 hsa-miR-146b-5p-4373178 
 

 
37 hsa-miR-31-4395390 
 

 
38 hsa-miR-19b-1*-4395536 
 

 
39 hsa-miR-672-4395438 
 

 
40 hsa-miR-875-3p-4395315 
 

 
41 hsa-miR-551b-4380945 
 

 
42 hsa-miR-149-4395366 
 

 
43 hsa-miR-92a-1*-4395248 
 

 
44 hsa-miR-549-4380921 
 

 
45 hsa-miR-550*-4380954 
 

 
46 hsa-miR-504-4395195 
 

 
47 hsa-miR-142-3p-4373136 
 

 
48 hsa-miR-330-5p-4395341 
 

 
49 hsa-miR-194*-4395490 
 

 
50 hsa-miR-148b*-4395271 
 

 
51 hsa-miR-221-4373077 
 

 
52 hsa-miR-194-4373106 
 

 
53 hsa-miR-339-3p-4395295 
 

 
54 hsa-miR-449a-4373207 
 

 
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55 hsa-miR-100*-4395253 
 

 
56 hsa-miR-146b-3p-4395472 
 

 
57 hsa-miR-378-4395354 
 

 
58 hsa-miR-93*-4395250 
 

 
59 hsa-miR-628-5p-4395544 
 

 
60 hsa-miR-486-5p-4378096 
 

 
61 hsa-miR-571-4381016 
 

 
62 hsa-miR-335*-4395296 


  
63 hsa-miR-323-3p-4395338 


  
64 hsa-miR-497-4373222 


  
65 hsa-miR-125a-3p-4395310 


  
66 hsa-miR-655-4381015 


  
67 hsa-miR-28-3p-4395557 


  
68 hsa-miR-636-4395199 


  
69 hsa-miR-923-4395264 
   
70 hsa-miR-518b-4373246 
   
We combine dysregulated miRNAs of all histopathological tumour groups in one 
table to differentiate between specific miRNAs which belong to the particular 
histopathological group. As we observed in above table there are 7miRNAs are 
which only exist in metastasis, 12 miRNAs in stages, 2 miRNAs in gender, 27 
miRNAs in grade and 9 miRNAs in Adjuvant chemotherapy. These miRNAs are 
specific only to histopathological groups. 
4.2.2 miRNAs differentiate primary and metastatic colon tissues  
In order to investigate miRNAs profile expression among the tissues classes, we 
performed differential expression analysis among the 47 primary and 18 
metastatic colon tissues and identified 17 miRNAs dysregulated among the 
patients, some of them have been reportedly associated with tumour activities in 
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colon cancer in the past. We observed up-regulation of 6 miRNAs (hsa-miR-636, 
logFC 1.57; hsa-miR-655, logFC 1.33; hsa-miR-135a*, logFC 1.28; hsa-miR-26a, 
logFC 1.25; hsa-miR-335*, logFC 0.89; hsa-miR-335, log FC 0.83) in primary 
tissue. Previously, hsa-miR-636 dysregulation has been reported in association 
with survival (Slattery et al., 2016) and down-regulation of hsa-miR-135a* linked 
to cell cycle regulation in colon adenoma cells (Schlormann et al., 2015). 
Similarly, up-regulation of hsa-miR-26a is associated with down regulation of 
CDK6 mRNA and induce apoptosis of colon cancer cells (Konishi et al., 2015). 
We observed up-regulation of two members of miR-335 family, previously 
involved in process of multiple tumorigeneses in colon tumours (Wang et al., 
2010).  
We also identified 11 up-regulated miRNAs (hsa-miR-769, hsa-miR-28, hsa-miR-
27b, hsa-miR-125a, hsa-miR-497, hsa-miR-424*, hsa-miR-378*, hsa-miR-323, 
hsa-miR-106b*, hsa-miR-15b*, and hsa-miR-143*) in metastatic tumors as 
compared to primary colon. Previously, down-regulation of hsa-miR-28 (Almeida 
et al., 2012) has been reportedly linked to reduced cell proliferation, migration and 
invasion in vitro, so the over-expression of hsa-miR-28 in our study indicate 
oncogenic effects on processes like cell proliferation and migration. Further 
studies based on dysregulation of hsa-miR-28 in colon cancers may provide 
reciprocate details of genes likely to involved in metastases. Higher expression of 
hsa-miR-27b has been associated with proof clinical response (Rasmussen et al., 
2013),  reportedly involved in suppressed tumour growth,  cell adhesion,  and 
invasion (Matsuyama et al., 2016). miRNAs hsa-miR-424* and hsa-miR-378*  
up-regulation reported being involved in lymph node metastases and poor 
prognosis (Wang et al., 2012, Wang et al., 2010). Other miRNAs with oncogenic 
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activities are hsa-miR-125a inhibit cell proliferation and induce apoptosis by 
targeting BCL2,  BCL2L12 and Mcl-1 (Tong et al., 2015) and miR-106b mediate 
inhibition of LT97 cell proliferation (Schlormann et al., 2015). 
 
Figure 3. Heatmap representation of miRNAs differentially expressed among primary and 
metastatic tissue classes.  
We identified 11 up-regulated miRNAs (hsa-miR-769, hsa-miR-28, hsa-miR 27b, 
hsa-miR-125a, hsa-miR-497, hsa-miR-424*, hsa-miR-378*, hsa-miR-323, hsa-
miR-106b*, hsa-miR-15b*, and hsa-miR-143*) in metastatic tumors as compared 
to primary colon. Previously, down-regulation of hsa-miR-28 (Almeida et al., 
2012) has been reportedly linked to reduced cell proliferation, migration and 
invasion in vitro, so the over-expression of hsa-miR-28 in our study indicate 
oncogenic effects on processes like cell proliferation and migration. 
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4.2.3 miRNAs differentially expressed among the stages 
Studies based on miRNAs specific to tumour stage and survival are vital for the 
understanding of tumour progression and origin sites (Slattery et al., 2015a). 
Therefore, we investigated miRNA expression across the different stages of colon 
cancer by performing univariate ANOVA analysis and identified 25 miRNAs 
differentially expressed (p-value 0.001) among the four stages. Of these, 11 
showed over-expression in stage I, 15 in stage II, 15 in stage III and 14 miRNAs 
in stage IV.  
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Figure 4. Heatmap representation of miRNAs differentially expressed among four stages of colon 
cancers.  
Surprisingly, none of the miRNA either showed continuous over-expression or 
under-expression from stage I to stage IV during the analysis which provides 
strong evidence of miRNAs ability of stage specificity. We observed similarities 
in the expression changes of miRNAs between stage I and II, and nearly the same 
numbers of miRNAs altered its expression from stage III to stage IV (heatmap). 
We also observed significantly decreased expression of miRNAs compare to stage 
III and IV in stage I and II tumours, suggests a shift in the pattern changes of 
miRNAs and can be differentiated in the presence of this signature. The overall 
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behaviour of miRNAs between primary stage I and II was same but upon 
evaluating individual miRNAs we observed a significant increase in expression of 
two miRNAs in stage II colon tumours (hsa-miR-200c*, logFC1.39 and hsa-miR-
181c*, log FC 1.06). Further analysis of these miRNAs could only reveal their 
ability to distinct between the stage I and II tumours along with their vulnerability 
to undergo metastases.     
Another interesting theme observed during analysis was that none of the miRNA 
expressed in primary stage I and II was associated with metastases, however, five 
significantly miRNAs (hsa-miR-15b*, hsa-miR-143*, hsa-miR-106b*, hsa-miR-
378* and hsa-miR-424*) over-expressed in stage III and IV. We further evaluated 
the relationship of these miRNAs for association with survival and their anti-
correlated impact on transcription sites of mRNA. 
4.2.4 Histological grades 
The investigation on expression patterns across the tumour grades shows 
significant (p-value 0.01) dysregulation of 34 miRNAs from well, moderate and 
poorly differentiations of colon tumour cells. Of these, 14 miRNAs showed over-
expression in well, 17 in moderate, and 21 in poorly differentiated tumour grades. 
As expected, we observed decreasing expression from well to poorly 
differentiated miRNAs.   
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Figure 5. Heatmap representation of miRNAs differentially expressed among three grades of colon 
cancer.  
 We have also investigated the association of tumour grades with primary and 
metastases colon tumour and observed nearly three miRNAs (hsa-miR-378*,  hsa-
miR-424*,  and hsa-miR-27b) have shown higher expression in poorly tumour 
differentiation as well as in metastatic colon tissues. However,  we observed over-
expression of two miRNAs (has-miR-135a*,  log FC 2.90 and hsa-miR-26a,  log 
FC 2.94) in well-differentiated tumour grades as well as also shown higher 
expression in primary tumour colons.    
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4.2.5 Adjuvant Chemotherapy 
Determining subset of high risks patient likely to get the benefit of chemotherapy 
could add valuable information to the clinical features in colon cancer metastasis 
potential and drug resistant (Li et al., 2016).  Genetic therapies treatments with 
miRNAs in a combination of chemotherapy and surgeries are essential for 
suppression of tumour growth in advanced-stage colon cancers (Okamoto et al., 
2016). Here we report dysregulation of 15 miRNAs after comparison of groups of 
patient served with adjuvant chemotherapy against comparing to who hasn’t. 
Among the 8 up-regulated miRNAs are (hsa-miR-15b*, logFC 2.59; hsa-miR-
143*, logFC 2.13; hsa-miR-106b*, logFC 1.92; hsa-miR-505, logFC 1.65; hsa-
miR-378*, logFC 1.36; hsa-miR-18a, logFC 0.75; hsa-miR-10b, 0.60; hsa-miR-
769, logFC 0.49). A closer look at the results shows that nearly five miRNAs have 
responded with high expression in patients served with chemotherapy also showed 
over-expression in metastatic tissues. Similarly, they have also shown correlation 
with at stage III and IV colon tumours.  
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Figure 6. Heatmap representation of miRNAs differentially expressed among histological groups 
of colon cancer patient who were treated with adjuvant chemotherapy versus who received no 
treatment.  
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Figure 7. Venn diagram summarising miRNAs dysregulated among five histological groups.   
 
We combine dysregulated miRNAs of all histopathological tumour groups on 
Venn diagram to differentiate between specific miRNAs which belong to the 
particular histopathological group. As we observed in above diagram there are 
7miRNAs are which only exist in metastasis, 12 miRNAs in stages, 2 miRNAs in 
gender, 27 miRNAs in grade and 9 miRNAs in Adjuvant chemotherapy. These 
miRNAs are specific only to histopathological groups. 
 
 
4.2.6 miRNA associated with prognosis in colon cancers 
We performed Cox-regression univariate analysis in order to identify miRNAs 
whose expression is associated with clinical outcome. Analysis was for conducted 
using all the colon tumour samples with respect to overall survival (OS) and 
disease-free survival (DFS) from the point of diagnosis till clinical end points 
54 | P a g e  
 
(death or recurrence of disease). As a result, we identified 10 miRNAs associated 
with clinical outcomes (table 7). Among these, 9 of them were significantly 
associated with OS and only one miRNA was linked to DFS. We further analyse 
these prognostic miRNAs by assessing their expression in different 
histopathological groups and found almost all the prognostic miRNAs were 
significantly dysregulated between them. For example, prognostic miRNAs (hsa-
miR-378* and hsa-miR-15b*) were dysregulated in metastatic patients, three 
grades (poorly, moderate and well differentiated), adjuvant chemotherapy (yes or 
no), and among the four stages of tumour progression. Similarly, we identified 
individual prognostic miRNAs which have shown dysregulation in one particular 
histology comparison such as, has-miR-183* uniquely expressed among the four 
stages of tumour samples, and two miRNAs (hsa-miR-92a-1* and hsa-miR-330-
5p) when we performed comparisons among the patient with different tumour 
grades.       
Table 7. Summary table of miRNAs associated with survival outcomes.  
 
miRNAs 
miRNAs significantly associated with prognosis 
No. HR Lower Higher P-value 
1 hsa-miR-378*-4373024 0.81 0.66 0.99 3.71E-02 
2 hsa-miR-15b*-4395284 0.81 0.69 0.95 5.56E-03 
3 hsa-miR-628-3p-4395545 1.3 1.04 1.62 1.95E-02 
4 hsa-miR-135a*-4395343 1.45 1.06 2 1.85E-02 
5 hsa-miR-183*-4395381 1.64 1.22 2.22 1.51E-03 
6 hsa-miR-330-5p-4395341 6.02 2.49 14.56 2.30E-11 
7 hsa-miR-323-3p-4395338 0.83 0.69 1 4.19E-02 
8 hsa-miR-125a-3p-4395310 0.56 0.33 0.97 3.69E-02 
9 hsa-miR-655-4381015 1.36 1.08 1.73 8.05E-03 
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10 hsa-miR-92a-1*-4395248 0.73 0.54 1 4.10E-02 
 
All the prognostic miRNAs were further divided into risk groups (high or low) 
according to their risk-score predictor. Prognostic miRNAs exhibiting Hazard 
Ratios less than one (HR < 1) were defined as “Protective” and miRNAs 
associated with Hazard Ratio greater than one (HR > 1) as “Risk-associated”. Five 
of the miRNAs associated with better prognosis (hsa-miR-378* (HR = 0.81, CI = 
0.66-0.99), hsa-miR-15b* (HR = 0.81, CI = 0.69-0.95), hsa-miR-323-3p (HR = 
0.83, CI = 0.69-1), hsa-miR-125a-3p (HR = 0.56, CI = 0.33-0.97), and hsa-miR-
92a-1* (HR = 0.73, CI = 0.54-1). Similarly, prognostic miRNAs such as hsa-miR-
628-3p (HR = 1.3, CI = 1.04-1.62), hsa-miR-135a* (HR = 1.45, CI = 1.06-2), hsa-
miR-183* (HR = 1.64, CI = 1.22- 2.22), hsa-miR-330-5p (HR = 6.02, CI = 
2.49-14.56), and hsa-miR-655 (HR = 1.36, CI = 1.08-1.73) were linked to worse 
prognosis. All of the risk-associated miRNAs were absent when we compared 
patients who have received adjuvant chemotherapy versus who hasn’t. A closer 
look at risk-associated miRNAs shows that high-risk hsa-miR-183* has shown 
higher expression in stage I and II compared to stage III and IV, could be used as 
a biomarker for early detection of colon cancer. We further performed Kaplan-
Meier analysis using prognostic miRNAs in order to calculate and illustrate 
survival curves.   
Further analyses were performed on prognostic factors by conducting univariate 
and multivariate analysis using histopathological information on its own (without 
the expression data). As a result, we found histological factor stage is significantly 
associated with prognosis of DFS (table 8) whereas histological factors such as 
stage, tissue type and use of adjuvant chemotherapy significantly associated with 
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OS prognosis (table 9). Following the cox regression analyses, we then assessed 
the quality of fitted models using analysis of deviance (-2 log likelihood) for the 
selection of co-variate which could impact on the association of prognostic factors 
with miRNA expression on the outcome prediction. The deviance-score analysis 
shows one-factors (stage level) model can be a best-suited model for DFS 
prognosis whereas, prognostic factors tissue type and stage level models for OS 
prognosis. Almost all the miRNAs exhibited their ability as an independent 
prognostic factors when evaluated using multivariate models for DFS and OS.   
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Table 8. Summary table of prognostic factors associated with DFS. 
Disease-free survival 
Histopathological factors 
 
Univariate Multivariate 
N(
n) 
HR %95 CI 
P-
Value 
HR %95 CI 
P-
Value 
Gender Female 25 1 
  
1 
  
 
Male 40 
0.96
86 
0.2591 
3.621 
0.962 
0.97
04 
0.25327-
3.718 
0.965 
Tissue Type Tumor 47 1 
  
1 
  
 
Mets 18 
2.89
3 
0.5843-
14.33 
0.193 
0.48
91 
0.03775-
6.337 
0.584 
Tumour Grade 
Continu
ous 
65 
1.03
2 
0.3754-
2.834 
0.952 
1.07
75 
0.35709-
3.251 
0.895 
Stage 
Continu
ous 
65 
2.46
4 
1.049- 
5.786 
0.038
45 
3.25
1 
0.64426-
16.405 
0.153 
Adjuvant 
Chemotherapy 
No 27 1 
  
1 
  
 
Yes 38 
2.55
8 
0.5244-
12.48 
0.245
4 
1.27
61 
0.22312-
7.298 
0.784 
 
Further analyses were performed on prognostic factors by conducting univariate 
and multivariate analysis using histopathological information on its own (without 
the expression data). As results, we found histological factor stage is significantly 
associated with prognosis of DFS in the table above.  
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Table 9. Summary table of prognostic factors associated with OS. 
Overall survival 
Histopathological factor 
 
Univariate Multivariate 
N(
n) 
HR %95 CI 
P-
Value 
HR %95 CI 
P-
Value 
Gender Female 25 1 
  
1 
  
 
Male 40 1.58 
0.682-
3.687 
0.28 
1.51
29 
0.63151-
3.6244 
0.352
99 
Tissue Type Tumor 47 1 
  
1 
  
 
Mets 18 
5.05
9 
2.243-
11.41 
0.0000
938 
1.26
36 
0.25292-
6.3128 
0.843
89 
Tumour Grade 
Continu
ous 
65 
0.62
56 
0.2618-
1.495 
0.291 
0.91
12 
0.36127-
2.2984 
0.775
61 
Stage 
Continu
ous 
65 
2.75
8 
1.646-
4.623 
0.0001
174 
3.47
53 
0.64426-
16.405 
0.015
4 
Adjuvant 
Chemotherapy 
No 27 1 
  
1 
  
 
Yes 38 0.72 
0.3285-
1.619 
0.43 
0.22
01 
1.26872-
9.5193 
0.001 
Histological factors such as stage, tissue type and use of adjuvant chemotherapy 
significantly associated with OS prognosis (table 9). Following the cox regression 
analyses, we then assessed the quality of fitted models using analysis of deviance 
(-2 log likelihood) for the selection of co-variate which could impact on the 
association of prognostic factors with miRNA expression on the outcome 
prediction. 
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4.2.7 miRNA, mRNA coupling analysis 
In order to established relation between miRNAs and their respective mRNA gene 
targets, we carried out target prediction analysis followed by Pearson correlation 
analysis. The main purpose of this proposed model is the biology of miRNA and 
the methods in prediction of gene targets. It has been widely known that the 
binding of miRNA during transcriptional activity degrade predicted targets, so 
only the anti-correlated predicted targets can prove to be the real ones. Second, the 
predicted targets are usually unreliable and cannot be implied in biological 
observation. Thirdly, only miRNAs showing the anti-correlation between its 
targets can and are more likely to play a role in functional activities.  
So for each prognostic miRNA, a list of putative candidate genes was extracted 
using five different predicting algorithms (table 10) followed by an independent 
correlation analysis. We focused on only anti-correlated miRNA, mRNA pairs 
according to the biology of miRNAs. The independent correlation analysis was 
performed among the pairs due to lack of correlation between the miRNAs and 
the predicted targets obtained from the five algorithms. For miRNA:mRNA pairs 
anti-correlation analysis, we isolated each miRNAs targets predicted by the five 
prediction algorithms and then extracted expression of the matching target genes 
from the mRNA expression sets. In total, we observed over-lapping of 1831 
(figure 9) genes among the predicted targets and the mRNAs genes differentially 
expressed among the colon subtypes. The top-anti correlated genes are highlighted 
in the table (table 11).     
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Table 10. Predicted targets of prognostic miRNAs.  
h
sa-m
iR
-6
5
5
 
APC, CDKN1C, DMD, FBN1, HK1, SGCB, MTM1, MYO5A, PTCH1, PAX6, EGR2, GPD2, APP, IFNG, LTBP1, HMGCR, IMPDH1, NR3C2, PPP3CA, ATP2B1, ATP2B4, SMAD5, PTER, 
GALK2, ZNF470, SIAH1, BRWD1, EI24, TULP4, ZDHHC9, CGGBP1, RBM33, TMEM64, CXCR4, EML1, FNIP1, MLLT10, ZCCHC11, PDLIM5, SEH1L, RFFL, SP3, GOPC, 
GOLGA8B, TNRC6B, TGFBR2, FNBP1L, CD47, NDEL1, ARFIP1, AHDC1, ARHGAP5, RHOBTB1, PPM1B, PHF12, CYFIP2, PDE4B, AGPAT3, USP9X, CDC42, PCDH17, WHSC1, 
SHPRH, HIPK3, ZNF436, WIPF1, KTN1, PAICS, VAV3, USP6NL, STRN3, CTBP2, TCF4, MEX3A, ACLY, XPO7, PHACTR2, SENP6, KDELR2, ZFAND5, RGS4, PCDH19, ZFYVE16, 
UBE4B, FBXO45, ADAM10, ADD3, ADM, ANK2, SLC25A5, ARHGAP6, CALU, CHD2, CHUK, CREBL2, DYRK1A, EP300, EPAS1, ESRRG, FOXC1, ING2, ATP2A2, BCL6, KLF5, 
CBFB, CDH2, CEBPG, COL4A1, COL11A1, GADD45A, DR1, EGR1, EIF4A2, EIF4E, GAS1, GNAI1, GNAQ, HOXB3, INHBB, ITGB1, ITGB8, KDR, MARCKS, MBD1, MEIS1, 
PPP1R12A, PDGFA, PIK3C2A, PLN, PNN, PPP1CB, PRKD1, MAPK1, MAPK9, PTPN1, PTX3, RAB5B, RDX, RGS1, SATB1, MAP2K4, SNAI2, SMARCE1, SNRPE, SNX1, SSB, 
RPS6KB1, UVRAG, VSNL1, WEE1, XPO1, YWHAZ, ZNF91, PTP4A1, FZD5, DYRK2, MAP4K3, GAS7, BCAS1, AGPS, CASK, TMEFF1, SLC25A12, PPAP2B, HSD17B6, NCOA1, 
EIF4G3, DYRK4, TRIM24, SOCS2, EIF2S2, SEMA5A, BTAF1, GMFB, RAB5A, PTTG1, SOCS6, JMJD1C, HOMER1, ACTL6A, BNIP2, DACH1, EPHA4, ETV5, ACSL3, ACSL4, BPTF, 
MLLT3, TSPAN7, CDK2AP1, ETF1, CCPG1, KIF3B, MAP4K4, ROCK2, SCAMP1, VPS4B, TMEM59, SPAG7, SEC22B, ETV1, JARID2, DNAJA3, CEBPB, GTF2H1, NFIL3, PPP1R3C, 
VEGFC, MAFB, RANBP9, LRRC32, KIF20A, YAF2, TOB1, SRRM1, SPRY1, IRX5, SMNDC1, MEOX2, NAB1, UCHL3, CD164, SEMA3A, SPON1, NEDD4, PBX3, GNAI3, EXOC5, 
DCTN6, CHL1, HSPH1, HOXA2, LMO4, CBX1, PNRC1, CALM1, RAC1, RBBP6, ZNF22, NR4A3, TLE4, WWP1, UBL3, WBP4, SEC63, RNF13, PAXIP1, CCT5, ZFPM2, MACF1, 
BACE1, CHIC2, CD2AP, FZD4, NT5C2, RAB3GAP1, RYBP, HEY2, KPNA6, MYO10, RAB3GAP2, SETDB1, ZNF281, BRD7, FLRT3, GREM1, AK2, BAZ2B, CLIC4, NRG1, SSX2IP, 
CHMP2B, TRPS1, SETD2, AP2A1, ZNF318, RNF11, DAPP1, SESN1, GOLIM4, NUP93, SERTAD2, EPM2AIP1, CEP350, UBAP2L, RNF44, WDR47, STK38L, MON2, WAPAL, ZNF423, 
TBC1D9, ZCCHC14, ANKRD28, LPHN3, AGTPBP1, SATB2, TRIM2, SASH1, DOCK9, LARP1, ADNP, ZNF521, KBTBD2, OPA1, WSB1, COL5A3, TRIM33, PHF20L1, UBE2J1, 
HECA, PACSIN3, BIRC6, FAM8A1, TUBE1, KLF2, TOB2, HSPA14, COPS7A, CTDSPL2, PHF20, KLF3, NKRF, RNF111, CDKN2AIP, FAM46A, ANKHD1, WHSC1L1, YTHDF1, Mar-
01, ECT2, TMEM30A, ASXL2, RSBN1, MBNL3, C17orf85, YOD1, ETNK1, ERRFI1, SLC38A2, ANKIB1, PLEKHA5, WDR44, ING3, NDFIP2, SLC39A10, EIF5A2, SMEK2, PELI1, 
USP31, HEG1, HACE1, WDFY1, KIAA1468, SH3RF1, LRCH2, CNTN3, GRAMD1A, NR2F2, RTN1, RAP2C, FAM60A, PELI2, GPBP1L1, TRIB2, SEC24A, XYLT1, RNF38, SLC30A5, 
REEP1, NADK, ATP13A3, FAM118B, SMC6, E2F8, PHC3, PGAP1, CEP135, FBXO11, NDFIP1, DICER1, DDHD1, SETD7, SGPP1, ANP32E, RNF146, COG3, CRISPLD1, ITCH, 
B3GNT5, FBXO30, TMEM117, KIAA1804, PCDH7, KBTBD8, FOXP1, GPR124, PURB, TP53INP1, TANC1, ABCC10, MAL2, CCND1, CCNE2, PHACTR3, DCBLD2, NIPBL, STXBP5, 
WDR20, FAM76B, ZNF23, PTPDC1, TMTC2, ARID2, UBE2E2, YTHDF3, PDIK1L, KBTBD6, AEBP2, USP43, CPNE8, NAP1L5, RDH10, RC3H1, AQP11,  SLC25A26, VKORC1L1, 
PAN3, SESTD1, MTDH, CMTM4, PIK3R1, CPEB2, SRPK2, CXorf23, PRICKLE2, SS18L1, KCTD1, QKI, IL18RAP, ALMS1, FANCL, SPTBN1, STON1, CEBPZ, ODC1, LSM14B, ZBP1, 
EYA2, SEMG1, SGK2, TGM2, RPN2 
h
sa-m
iR
-
1
2
5
a-3
p
 
IGF2BP2, EXOC7, SHANK3, KIF2A, RGS4, E2F3, GCG, MBD1, PPP1CB, MAP2K1, SMARCA2, DACH1, RPS6KA3, TSC22D1, MAB21L2, MAN1A2, PKIA, RNF139, BRCA1, RYBP, 
EPB41L3, TRPS1, KLHL20, NLK, HP1BP3, BNC2, NDE1, CHFR, ETNK1, NUFIP2, CFL2, NDFIP1, ZNRF3, C1orf198, TMEM129, GPX1, IER5L, SMAD2, SNX21, IRF2BP2, GNAS, 
ADD3, ANK2, BCAT2, LDB2, DPYSL2, FOXC1, CAV1, CTGF, GNAI2, GALNT4, RNGTT, FAP, MAP1B, PGRMC2, TRIO, BACE1, RAB3GAP1, G3BP2, NPTN, SEC14L2, CNOT4, 
BAZ2A, NRG1, TNFRSF21, SLK, SIPA1L1, RAB4B, EVL, CTDSPL2, F11R, FAM46A, Sep-11, GATAD2B, SCUBE2, BTF3L4, NR4A3, GANAB, DHX57 
h
sa-m
iR
-3
2
3
-3
p
 
GJA1, HK2, MET, ATXN1, APP, ATRX, GAD1, ERBB2IP, IFRD1, BRWD1, CGGBP1, ENAH, MXI1, FNIP1, MLLT10, PPM1B, ARL5A, USP9X, ACTR3B, GLIS3, ZNF706, HIPK3, 
SENP7, PCBP2, TGFA, RAP1GDS1, TLE3, NRXN3, ACVR2A, KLF5, CCND2, CLCN4, PPP1CB, PRKAR1A, PTPRF, WEE1, AGPS, TNFSF11, CDKN1B, COL12A1, CREB1, DDX6, 
BPTF, DAPK1, EFNA3, FOS, TAF12, YAF2, MAN1A1, MAT2A, MAP3K5, NFYB, PBX3, PKN2, PGRMC2, MAP4K5, LRBA, WWP1, TMF1, ZIC2, ZFPM2,  APPL1, FBXL5, G3BP2, 
MYLIP, FLRT3, LRP12, RNF11, TMOD3, PHF14, EDEM1, SERTAD2, DNAJC6, MELK, AAK1, USP33, ATP11A, LARP1, NIPBL, CNOT6, ZZZ3, UTP11L, GOLT1B, NLK, CDKN2AIP, 
FAM46A, SUV420H1, ANKHD1, COMMD8, PRPF40A, SCYL2, IFT57, TMEM30A, RSBN1, UBAP2, YOD1, PLEKHA5, C11orf30, SMEK2, GALNT1, GATAD2B, SRGAP1, PTBP2, 
HSPA2, MARCKSL1, FRY, TBL1XR1, PHC3, PGAP1, CHD9, CPEB4, SETD7, PCDH7, DAB2IP, PURB, SLC44A1, SLC30A7, KCTD12, UBLCP1, MIER3, UHRF2, JAZF1, ZNF326, 
CREB3L2, C1orf52, NOTCH2NL, TIMP3, SMAD5, ATP1B1, RUNX1, MTUS1, SMAD2, OSBPL8, TFEC, GOLGA8B, ARFIP1, PHF12, PDE4B, STAG2, TCF4, PHACTR2, PDS5A, 
PDE4D, ACVR1, ANK2, CDC5L, CREBL2, ALCAM, ARF6, CPE, FMR1, GCLM, LAMC1, LBR, PIK3C2A, PPP1CC, PSMD10, SH3BGRL, SPTBN1, VSNL1, RNMT, EGR3, MED1, 
MAP4K4, ATF1, ROCK1, DNAJB6, ARL4C, RBM5, PSME3, TBX3, NR4A2, PLCL1, RBBP6, FBXO8, RYBP, TRPS1, MTCH2, GHITM, NEK6, ZNF516, KIAA0355, PJA2, TBC1D4, 
WAPAL, SMG1, CAMTA1, LPHN3, TMEM87A, TIPARP, AUTS2, MTMR2, AKAP11, RAPGEFL1, PHF20, BNC2, KIAA1598, CAND1, SLC38A2, RIN2, ANKRD50, ABHD6, CGN, 
LRRN1, RAB18, ZNF148, XYLT1, BCL11A, GPBP1, RNF128, SGPP1, SNX27, ZNF566, PPTC7, TMED6, LSM14B, ZNF564, RBM24, ARL5B, SPTY2D1, B3GALTL, NUP43 
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h
sa-m
iR
-3
3
0
-
5
p
 ENG, ATXN1, GPD2, PAFAH1B1, RARG, ZDHHC9, BCAP29, BTBD11, FNDC3A, SHANK3, TCF4, XPO7, ITGA5, STC1, FZD5, TAGLN2, HRK, NR5A2, EGR3, EPHB3, ESRRA, 
ILF3, SNRPA, SLC27A4, TLN1, SOX12, SLC19A2, THBS3, BTBD3, METAP1, RCOR1, FAM53C, RFWD3, PAG1, GRIPAP1, LYRM2, MPP5, DGCR14, COPS7B, KCTD15, TBL1XR1, 
CBLL1, PVRL4, FAM107B, FBXL20, MAG, CHKB, MIER3, RALGPS2, ANKRD52, CMTM8, AUP1, ERBB2IP, C20orf194, VLDLR, NDEL1, CSNK1G3, SEC14L1, C4orf19, BCL2L1, 
DPYSL2, RHOA, CENPB, ITGA2, MAP1A, FGF18, DAG1, RPS6KA3, PRKAB2, MAP1B, MEOX2, PBX3, PKIA, SEC63, NRG1, VGLL4, CEP350, LARP1,  YBX2, NLK, KLF3, F11R, 
PPP3CB, BCL11B, LCOR, GLIS2, C9orf24, BTN2A1, CAPN12, NHS 
h
sa-m
iR
-1
8
3
 
NR3C1, CYP2B6, GOLGA7, PKP4, LPHN1, TTC7B, NCDN, KIAA0101, CSNK1G3, FRMD6, MIER1, KIAA0368, REPS2, TCF4, KIF2A, MRVI1, GNG4, PDE4D, ARHGAP6, ACVR2A, 
CLCN3, HBEGF, EGR1, LRP6, PLAGL2, PRKACB, PTPN4, RCN2, ROBO2, SLC6A6, STC1, CDK5R1, GMFB, HOMER1, ACVR1B, EPHA4, FOXA1, BUB3, ICA1, GTF2H1, RALA, 
YAF2, LHFPL2, CD164, SLC35A1, RGS14, MAP4K5, QKI, RAB35, DUSP10, XPOT, ZFPM2, AP3M1, RYBP, LIMD1, TRAM1, SESN1, BZW1, TOMM70A, ZHX2, STK38L, FRYL, 
ZDHHC17, ZFYVE26, CNOT6, RNF138, RAB8B, DPP8, PHF10, ING3, PLEKHA3, NUDT4, SCYL3, ARHGAP21, GPAM, NTN4, BACH2, ZDHHC6, WHSC1L1, TCF7L2, ARHGAP18, 
CYYR1, SLC44A1, FAM91A1, VPS37A, PLCB4, RORC, OSBPL8, NCK2, ERBB2IP, L3MBTL3, EI24, ZDHHC9, ENAH, TMPO, RHOBTB1, AMD1, SIRPA, TTC14, SLC25A36, CHD2, 
CTGF, HLF, IDH2, ITGB1, PFN2, PIM1, PLAG1, PPP2R2A, PRKCI, CX3CL1, SNX1, TCF12, UBE2V2, DCHS1, SOCS6, BNIP3L, RPS6KA3, MTMR6, MTA1, MED1, POLR2D, SEL1L, 
DMXL1, IRS1, MAP3K4, UNC13B, NFAT5, TLE4, MYO1B, SACS, ATP2C1, PDCD4, ZNF592, KIAA0355, SIN3A, AUTS2, YPEL5, LRRC1, AGPAT5, SMPD3, PLEKHA5, EML4, 
ANKRD50, GATAD2B, MBNL1, TSPYL4, GREM2, ANKRD13C, BRMS1L, PCGF5, FOXP1, MAL2, COLEC12, PPP1R14B, PRICKLE2 
h
sa-m
iR
-1
3
5
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APC, GHR, GJA1, INSR, NPC1, COL5A2, ADRA2A, FKBP1A, RARA, RARB, SMAD2, EDA, SIAH1, SDCBP, IGF2BP2, CREB5, C6orf120, ARNTL, CSNK1G3, EXTL2, PPM1B, 
ATP6V1C2, PTPRD, ABCE1, CEP170, RRBP1, NET1, HIPK3, MEGF9, FOXN3, Sep-08, XPO7, ZFAND5, FBXO45, SLC25A5, TRIM23, CENPB, MEIS2, TNFRSF11B, P2RY2, PLCG1, 
PPP1CC, SMARCA2, SMARCE1, SSR1, TRPC1, PDHX, FZD1, NCOA1, USP13, EFNB2, ACVR1B, COL12A1, DAG1, DUSP8, B4GALT5, KIF3B, ARHGEF6, ROCK2, PGGT1B, 
PIK3R2, EPHA3, ROCK1, EOMES, BCAT1, EFS, DNAJA2, MAN1A1, PDE4A, LYPLA1, CAP2, SLC35A1, GNA13, TCFL5, RALBP1, PIM2, SHOC2, SIRT1, TBK1, MAPRE2, 
CORO1C, VGLL4, SERTAD2, ARHGAP11A, TBC1D4, JOSD1, CHSY1, STK38L, WAPAL, ZCCHC14, CAMTA1, KIAA1033, ARHGEF4, NBEA, CDC40, YBX2, RNF138, PHF20, 
KLF3, POGK, TRPM4, PALMD, PRPF40A, DET1, HMG20A, BRWD1, NDFIP2, SLC39A10, DOLPP1, INTS2, KIAA1468, LRRN1, ZFYVE28, ZDHHC6, SMURF2, BCL11A, BCL11B, 
SLC25A32, ANP32E, KCTD10, ARL6, LCOR, C1orf198, DIRC2, TRIM41, SLC44A1, SOCS4, PANK1, SP1, PPTC7, SLC39A13, LONRF1, ACOT4, MIER3, YTHDF3, DGKH, SLC9A9, 
IDH3G, UBR1, IL6ST, SPTBN1, MTDH, ATXN1, OTC, CACNA1D, NR3C2, SMAD5, PTER, MTUS1, GPM6B, GOLGA7, OSBPL8, SP3, VLDLR, TNRC6B, CD47, CSNK1A1, CD68, 
TMEM70, TTC14, MYO1C, PLAGL1, ZBTB34, RAP1GDS1, PCMTD2, ANK3, ARHGAP6, BACH1, PRDM1, LDB2, EMP1, HIF1A, ALCAM, ATP1B1, FRK, GNAQ, KPNA3, MAN2A1, 
PDGFA, PLAG1, PTPN1, RAB5B, SKI, RPS6KB1, ZKSCAN1, CNTNAP1, GAS7, KLF4, COX5A, DUSP5, ESRRA, TGFBR1, AKT3, PTK2, TOPORS, MAT2A, SEMA3A, TXNIP, API5, 
AHCYL1, CPLX1, QKI, TMED10, UTRN, ANGPTL2, BACE1, TLK1, TNPO2, BZW2, ORMDL2, CDR2L, RGL1, RCOR1, PSD3, GULP1, TMEM9, Mar-05, ZNF654, ST7, NUDT4, 
SMEK2, PELI1, CRAMP1L, PTBP2, PELI2, SNX16, NUCKS1, ELOVL6, SPSB1, SETD7, RAB1B, SEH1L, ZNRF3, SLITRK6, ASPH, PURB, CTTNBP2, MBD6, NAGS, AEBP2, 
FBXL16, FAM84B, CHMP4B, BCL9L, KCTD1, TSEN54, CAPN3 
h
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 BTK, PTEN, ATXN1, ATRX, IGF1R, PPP3CA, ZCCHC11, Sep-07, DCTD, BTBD11, CUL4B, MEX3A, PCDH19, CPD, MAPK6, TCF7, PIP5K1B, BPTF, DLG5, CCDC6, RBL2, YAF2, 
PAIP1, ZBTB6, TLK1, ZNF516, KIAA0922, KBTBD2, LSM14A, LUC7L2, NLK, CAMK2N1, EPB41L4B, SPIRE1, NUFIP2, PPP3CB, PTBP2, FAM60A, FRY, LSM12, MIER3, PAN3, 
CREM, AMPD3, SAMD13, TNRC6B, PLEKHG1, TFAP2A, PCDH17, CYLD, TRIM23, BPGM, CSNK1D, GCLM, HLF, ISL1, KPNA1, PPP2R1B, RPS6KB1, KIF3B, MAP4K4, GPM6A, 
SEC23A, ADAMTS1, CBX3, FBXL3, TRPS1, VAMP2, ZBTB11, ZBED4, SIN3A, TRIM33, UBE2J1, LIMA1, RSBN1, EML4, SLC39A10, DCUN1D1, SLAIN2, RNF38, SMC6, ITCH, 
CHKB, BTF3L4, MAMDC2, JAZF1, SUPT3H 
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ADRB2, CLCN5, FGFR2, INSR, MYO5A, PTCH1, PEX5, PAFAH1B1, APP, RARB, SMAD5, RFWD2, PLEKHA1, ACTR2, EDA, CTNNBIP1, TSC22D3, TMCC1, ZHX1, SERBP1, 
BCL7A, MINK1, AMMECR1, ARHGAP5, USP14, PCDH17, SIDT2, PTPRD, SLC9A6, SLC12A2, NCOR2, SHANK3, MYO1C, SCN3A, SMARCD2, TMEM100, PHACTR2, PID1, 
UBE4B, CALU, CAMK2G, CCNE1, CCNT2, CHEK1, CNN1, ESRRG, ACP2, CLCN3, E2F3, EIF5A, EZH1, GABPA, IHH, KDR, LAMC1, MAP1A, PIM1, PLAG1, PLRG1, PSMD7, 
PTPN3, PTPN4, CX3CL1, SSR1, STC1, TRPC1, CUL2, CBX4, PPAP2A, PPAP2B, CDK5R1, FUBP1, WASL, FASN, FKBP1B, FKBP5, COPS2, TRIP10, ARHGDIA, COL12A1, DACH1, 
DVL1, EGR3, ACSL4, HDGF, KIF5B, RPS6KA3, STX1A, AXIN2, KIF23, TBPL1, SPAG7, ETV1, CRKL, GLUD1, HAS2, PCMT1, HSPG2, IRS1, PDIA6, SMAD7, MAP3K4, MEOX2, 
CD164, RBM12, SEMA3A, USP15, SPTLC1, POLR3F, DYNLT3, USP3, EXOC5, BTG2, RBBP6, SLC2A3, SOS2, TAF5, WWP1, UBL3, NUP50, PXMP4, ACOT7, SHOC2, AP3M1, 
CHORDC1, LMOD1, EPB41L1, RYBP, HEY2, MAPRE1, MMD, NRBP1, NRG1, HSPA4L, CAPN6, TRAM1, SESN1, PDCD4, LRIG2, COBLL1, RAB11FIP2, DZIP1, WDR47, WAPAL, 
KIF1B, ARHGEF9, CAMSAP1, KBTBD2, LRIG1, UBE2J1, RAB4B, ACSL5, RNF138, PHF20, SLC22A17, APLN, SIX4, BAIAP2, KIF21A, CNNM2, TASP1, Mar-05, RNF125, CDCA4, 
IPO9, ZNF532, RSBN1, EPB41L4B, YOD1, ETNK1, ANKIB1, PLEKHA5, CYP26B1, FEM1C, CCDC47, SLC39A10, SALL4, GALNT1, DMTF1, RAP2C, BACH2, SEC24A, EGLN1, 
LPPR2, KLC2, BCL11B, CHAC1, ATP13A3, SLC25A22, DHDDS, DICER1, SLC41A2, SLITRK6, KIAA1804, RSPO3, MAP3K9, PURB, ARHGAP18, CDC42, AMOTL1, ZAK, ZNRF2, 
ANKRD13B, FAM81A, C9orf69, EED, PIK3R1, OGT, ARRDC4, CARM1, GHR, FKBP1A, GRIN1, HTR4, PDE3B, RARG, SIAH1, BRWD1, CSDE1, Sep-02, ENAH, LPHN1, ZC3H12B, 
FNTA, MYADM, TNRC6B, USP9X, DCUN1D4, CYLD, TTC14, PVRL2, ZNF436, IRF2BP2, FNDC3A, AATK, MYBL1, USP6NL, ZBTB34, PTAR1, HIGD1A, XPO7, PHF21A, ZBTB10, 
ADSS, ANK2, CDX2, CHD2, CPD, EIF4B, ACVR2A, CCND2, CLCN4, FGF2, GRB2, KPNA1, LRP6, PEX13, MAPK9, MAP2K1, PTPRR, SORT1, SALL1, ATXN2, SRPK1, RPS6KB1, 
TCF3, TGFBR3, WEE1, YWHAH, TAF15, DYRK2, PPM1D, CNTNAP1, AP1S2, BTAF1, SH2D2A, MAP7, SOCS6, ESRRA, MTMR4, MED1, KIF3B, JARID2, RELN, CBFA2T3, MYB, 
CCDC6, AKT3, DLL1, ABCF2, TSPAN5, RBM6, PURA, RTN3, SMYD5, YAP1, DYNC1LI2, PBX3, IVNS1ABP, GNAI3, SLC20A2, SYPL1, SPTBN2, TLE4, DNAJB4, WIF1, SUPT16H, 
WHSC1, BACE1, CD2AP, CLDN12, TLK1, PHLDA3, BAZ2A, SOCS5, AP2A1, CARD10, GCC2, HELZ, FRYL, SATB2, TRIM2, SYNE1, CCDC28A, TMEM87A, OSBPL3, PHF19, 
G0S2, GOLT1B, DCTN4, CAB39, RAPGEFL1, CRIM1, RAB8B, BFAR, GALNT7, RNF111, OTUB1, LRRFIP2, ZCCHC2, CHD7, CDC37L1, STX17, Sep-11, RCOR3, ARHGAP12, 
ZNF654, TBC1D19, TMEM55A, ASNSD1, CHPT1, CLDN2, DOLPP1, DCUN1D1, JPH1, GATAD2B, USP31, PPM1A, PPP3CB, FAM60A, PELI2, TGIF2, SAV1, SNX16, RNF38, CCNJL, 
HMBOX1, TBL1XR1, PHC3, KLHL18, C1orf21, SEH1L, GABARAPL1, SH3BGRL2, PHF20L1, PCGF5, SCOC, GPR124, SYDE1, RHPN2, CCND1, CDKN2B, SLC44A1, ZSWIM3, 
FAM91A1, SPRED1, PDIK1L, RBM24, N4BP1, AEBP2, ODF2, AQP11, C15orf37, CPEB2, RASSF5, ZNF326, KCTD1, E2F7, QKI, CAPN3 
h
sa-m
iR
-3
7
8
 
FANCA, NR3C1, PAFAH1B1, IGF1R, ATP2B4, GPM6B, FOXP4, ZHX1, PAPD5, GRSF1, KIF2A, Sep-08, RAP1GDS1, PDE4D, BMP2, TCF12, FZD5, FKBP5, CHST2, CALD1, XPR1, 
ABCF2, DYNC1LI2, RBM14, EXOC5, EPB41L3, RANBP6, DMXL2, AHCTF1, CAB39, CHD8, TRIB2, HSPA12A, PURB, GPT2, FMNL3, CREM, HIPK3, SLC7A6, IRF2BP2, SHANK3, 
DYRK1A, CELSR3, CENPB, GRB2, HOXB3, PLAG1, MAPK1, PDIA4, VAT1, ZFPM2, KPNA6, AAK1, CDC40, VANGL2, XPO5, NUFIP2, DHX36, KIAA1522, PAPOLA, DCBLD2, 
PDIK1L, ANKRD52, PTPLB, HDDC3 
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So for each prognostic miRNA, a list of putative candidate genes was extracted 
using five different predicting algorithms (table 10) followed by an independent 
correlation analysis. We focused on only anti-correlated miRNA, mRNA pairs 
according to the biology of miRNAs. The independent correlation analysis was 
performed among the pairs due to lack of correlation between the miRNAs and 
the predicted targets obtained from different algorithms. 
 
Table 11. Table of top anti-correlated miRNAs and their target genes.  
miRNAs Gene 
miRNA:mRNA 
Pearson correlation 
miRNAs Gene 
miRNA:mRNA 
Pearson correlation 
hsa-miR-
378*   
hsa-miR-
330-5p   
 
TMEM
171 
-0.05 
 
DNAJA3 -0.18 
 
ODC1 -0.03 
 
C16orf54 -0.08 
 
ACO2 -0.05 
 
TCF7 -0.11 
 
PAFAH
1B1 
-0.04 
 
NR0B2 -0.19 
 
PLOD1 -0.11 
 
CEP250 -0.04 
 
TGM2 -0.05 
 
TRPC4A
P 
-0.06 
 
CTBP2 -0.18 
 
CDK5R
AP1 
-0.12 
 
NR3C1 -0.02 
 
EPS8L3 -0.03 
 
UTP18 -0.15 
 
ZDHHC9 -0.17 
 
FANC
A 
-0.12 
 
FAM107
B 
-0.08 
 
TCN2 -0.05 
 
RCSD1 -0.03 
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EPB41
L3 
-0.09 
 
LCOR 0.00 
 
RPN2 -0.04 
 
SHD -0.11 
 
HMGB
2 
-0.13 
 
GLOD5 -0.15 
 
PTPLB -0.04 
hsa-miR-
323-3p   
 
KLC1 -0.02 
 
AGT -0.03 
 
PRKCD
BP 
-0.01 
 
E2F1 -0.03 
 
NAT10 -0.01 
 
HK2 0.00 
 
SIGLE
C1 
-0.13 
 
EXO1 -0.08 
 
SLC26
A6 
-0.05 
 
TTK -0.02 
 
UHRF1 -0.11 
 
DFFB -0.08 
 
ACSS2 -0.15 
 
SPC25 -0.05 
hsa-miR-
15b*    
OIP5 -0.08 
 
ARL6I
P5 
-0.16 
 
SELENB
P1 
-0.14 
 
PAFAH
1B1 
-0.08 
 
NUSAP1 -0.04 
 
PPT1 -0.04 
 
TIMM23 -0.01 
 
SMAR
CD2 
-0.10 
 
E2F8 -0.02 
 
TOMM
34 
-0.04 
 
SETD7 -0.07 
 
ADAM -0.04 
 
C9orf41 -0.04 
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12 
 
CD48 -0.05 
 
CMTM8 -0.18 
 
CXCL1
0 
-0.10 
hsa-miR-
125a-3p   
 
STC1 -0.07 
 
ETV4 -0.04 
 
ZW10 -0.05 
 
TSEN54 -0.07 
 
FKBP1
B 
-0.09 
 
AHCY -0.18 
 
NCOR2 -0.05 
 
CTBP2 -0.13 
 
SMYD
5 
-0.24 
 
TUBG1 -0.05 
 
GART -0.08 
 
POLE2 -0.05 
 
CHEK2 -0.16 
 
SLC26A
3 
-0.05 
 
OIP5 -0.07 
 
CEP250 -0.05 
 
TGIF2 -0.09 
 
FAP -0.01 
 
DUS1L -0.05 
 
TMEM9
7 
-0.06 
 
SRPRB -0.14 
 
DUSP7 -0.16 
 
FAM60
A 
-0.17 
 
CSGAL
NACT2 
-0.09 
 
SLC15
A4 
-0.19 
 
ZNF703 -0.20 
 
C10orf5
4 
-0.03 
 
MRRF -0.05 
 
ACSS2 -0.11 
 
ZNF511 -0.18 
hsa-miR-
628-3p    
ZNRF3 -0.31 
 
DNAJA -0.01 hsa-miR-
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3 655 
 
PKP4 -0.16 
 
DNAJA3 -0.14 
 
STK17
B 
-0.11 
 
SUV39H
2 
-0.08 
 
GPR19 -0.10 
 
AFG3L2 -0.14 
 
ASPM -0.13 
 
CALU -0.15 
 
FAM3
D 
-0.30 
 
WSB1 -0.02 
 
SAMD
13 
-0.24 
 
ETV5 -0.04 
 
MARV
ELD3 
-0.28 
 
CCNA2 -0.15 
hsa-miR-
135a*    
PTTG1 -0.23 
 
TSEN5
4 
-0.03 
 
BUB1B -0.04 
 
RRM1 -0.03 
 
MMP7 -0.20 
 
TNC -0.15 
 
TLE4 -0.08 
 
CHSY1 -0.01 
 
PLK4 -0.09 
 
DUSP4 -0.04 
 
CCNE2 -0.10 
 
IL6ST -0.03 
 
NR3C2 -0.14 
 
SRPX -0.11 
 
TNFAIP
6 
0.00 
 
TCP11
L1 
-0.04 
 
CHRNA
5 
-0.01 
 
CD36 -0.01 
 
RNF11 -0.16 
 
DUT -0.01 
 
SPON1 -0.02 
 
FAP -0.01 
 
AHCYL2 -0.16 
 
COL5A -0.03 
 
CCPG1 -0.14 
67 | P a g e  
 
2 
 
FAM10
7B 
-0.02 
 
SELENB
P1 
-0.10 
hsa-miR-
183*    
SLC38A
2 
-0.14 
 
TSEN5
4 
-0.01 
 
KIF20A -0.22 
 
ACO2 0.00 
 
HSPA14 -0.11 
 
EBNA1
BP2 
-0.08 
 
E2F8 -0.11 
 
NR3C1 -0.02 
 
FAM60A 0.00 
 
PKP4 -0.07 
 
A1CF -0.16 
 
KIAA0
101 
-0.01 
 
CENPK -0.18 
 
TARBP
1 
-0.08 
 
SH3RF1 -0.19 
 
PCK2 -0.17 
 
UHRF1 -0.18 
 
PHYH -0.08 
 
ANKRD
44 
-0.05 
 
DUSP4 -0.12 
hsa-miR-
92a-1*   
 
CXCL1
0 
-0.10 
 
TNC -0.10 
 
TLE4 -0.15 
 
RNASE1 -0.09 
 
LSM6 -0.10 
 
CLDN7 -0.04 
 
EPB41
L3 
-0.06 
 
KNTC1 -0.01 
 
PBXIP1 -0.03 
 
KLC1 -0.12 
 
HSD17 -0.10 
 
DUS1L -0.12 
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B11 
 
FAM10
7B 
-0.13 
 
EXOSC5 0.00 
 
CCND
BP1 
-0.06 
 
TMEM5
2 
-0.04 
 
GPR34 -0.02 
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In order to established relation between miRNAs and their respective mRNA gene 
targets, we carried out target prediction analysis followed by Pearson correlation 
analysis. The main purpose of this proposed model is the biology of miRNA and 
the methods in prediction of gene targets. It has been widely known that the 
binding of miRNA during transcriptional activity degrade predicted targets, so 
only the anti-correlated predicted targets can prove to be the real ones. Second, the 
predicted targets are usually unreliable and cannot be implied in biological 
observation. Thirdly, only miRNAs showing the anti-correlation between its 
targets can and are more likely to play a role in functional activities. 
We focused on only anti-correlated miRNA, mRNA pairs according to the biology 
of miRNAs. The independent correlation analysis was performed among the pairs 
due to lack of correlation between the miRNAs and the predicted targets obtained 
from the five algorithms. For miRNA:mRNA pairs anti-correlation analysis, we 
isolated each miRNAs targets predicted by the five prediction algorithms and then 
extracted expression of the matching target genes from the mRNA expression sets. 
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Figure 8. Venn diagram showing common genes among the predicted targets and mRNA 
expression set.  
 
In total, we observed over-lapping of 1831 (figure 9) genes among the predicted targets 
and the mRNAs genes differentially expressed among the colon subtypes. The top-anti 
correlated genes are highlighted in the table (table 11). 
 
4.2.8 Subtyping colon cancer and signatures in mRNA identified by gene 
expression data  
We performed integrated analysis in order to identify miRNAs whose expression 
is correlated with inverse expression of mRNA targets in primary colon 
expression set. Therefore, we performed mRNA expression profiling across 585 
primary colon samples and identified molecular signatures. In the first step, we 
performed unsupervised K-mean consensus clustering to uncover potential 
subtypes of colon tumour on the basis of the similarities of their gene expression 
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values of 10794 unique genes. We run K=2 to 6 in core K-mean clustering, two 
molecular subtypes could be identified when K=2 and the cluster consensus was 
0.81 and 0.87 for each subtype with 150 and 435 samples. When K=5 (figure 10), 
the unsupervised clustering reached the highest consensus 0.88 and 0.99. 
Therefore, we named these subtypes as C1 with 146 samples, C2 with 60 samples, 
C3 with 232 samples, C4 with 120 samples and C5 with 27 samples. 
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Figure 9. Results from unsupervised K-mean consensus clustering showing running value of K= 2 to 6. 
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We further carried out differential expression among the five predicted subtypes 
in order to identify the most discriminating genes among them. We performed 
ANOVA analysis among the predicted subtypes and selected 716 significant 
(adj.p.val < 0.001) genes for the two-dimensional average linkage hierarchical 
clustering. The clustering analysis divided differentially expressed genes into four 
large sub-groups with different expression subsets represented in the heatmap 
(figure 11).  We further performed gene ontology enrichment analysis for each 
identified subgroup in order to explore potential cellular processes, molecular 
functions and biological pathways. The DAVID analysis (table 12) showed that 
the Cluster I consist of 117 genes was significantly (p-value <0.01) enriched with 
lipid biosynthesis process, sodium channel regulatory activity, positive regulation 
of metabolic process, digestion, cellular respiration and inorganic anion transport 
GO terms. Hierarchical clustering analysis shows that majority of genes from this 
cluster were up-regulated in C2 and C4 subtypes of colon cancers. We also 
observed PPAR signalling and mitochondrial carnitine palmitoyltransferase (CPT) 
system pathways contributed by PPARA, HMGCS2, FABP1, PCK2, CPT1A and 
ACSS2 genes. Cluster II: is the largest clusters identified by hierarchical 
clustering consist of 348 genes and were up-regulated in a C5 subtype of colon 
cancers. We observed over-representation of cellular processes such as cell cycle, 
metabolic processes, cell division, DNA and RNA replication, cell cycle check 
points, chromosome organization, DNA repair, ATP binding, DNA and RNA 
processing, and signal transduction. The cluster genes also showed enrichment of 
cell cycle, mitotic, cell cycle, DNA replication, pyrimidine replication, DNA 
repair, CDC20 mediated degradation of Nek2A, the role of BRCA1, BRCA2 and 
ATR in cancer susceptibility and p53 signalling pathways.  
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Similarly, Cluster III genes were mostly up-regulated in C1 and C3 subtype of 
colon cancer. There were 121 genes enriched with intracellular cellular signalling, 
cellular response, and ion homeostasis GO terms. We also identified Fc Gamma 
R-mediated phagocytosis pathway with in this cluster. Cluster IV: is consist of 
134 highly dysregulated in C1 and C5 subtype of colon cancer. Enrichment 
analysis shows over-representation cellular processes such as extracellular matrix, 
biological adhesion, metabolic process, inflammatory response, cell proliferation 
and cell differentiation, and endopeptidase activity. We also observed ECM-
receptor interaction signalling and focal adhesion pathways within this cluster.     
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Figure 10. A heatmap showing two-dimensional average hierarchical clustering of five predicted 
colon subtypes.   
 
We further carried out differential expression among the five predicted subtypes 
in order to identify the most discriminating genes among them. We performed 
ANOVA analysis among the predicted subtypes and selected 716 significant 
(adj.p.val < 0.001) genes for the two-dimensional average linkage hierarchical 
clustering. The clustering analysis divided differentially expressed genes into four 
large sub-groups with different expression subsets represented in the heatmap 
(figure 11).  We further performed gene ontology enrichment analysis for each 
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identified subgroup in order to explore potential cellular processes, molecular 
functions and biological pathways. 
Table 12. Function analysis of four subgroups identified from unsupervised clustering analysis.   
Heatmap 
Clusters 
Go terms/pathways 
Cluster 1 
Lipid biosynthetic process 
Steroid binding 
Sodium channel regulator activity 
Secondary active sulfate transmembrane transporter activity 
Mitochondrion 
PPAR signaling pathway 
Mitochondrial membrane 
Sulfate transmembrane transporter activity 
Sulfate transport 
Mitochondrial envelope 
Excretion 
Positive regulation of fatty acid metabolic process 
Mitochondrial part 
Mitochondrial inner membrane 
Organelle envelope 
Envelope 
Steroid biosynthetic process 
Organelle membrane 
Organelle inner membrane 
Digestion 
Inorganic anion transport 
Aerobic respiration 
Cellular respiration 
Mitochondrial carnitine palmitoyltransferase (cpt) system pathway 
Inorganic anion transmembrane transporter activity 
Cluster 2 
Mitotic cell cycle 
Cell cycle 
Cell cycle phase 
Cell cycle process 
M phase 
Mitosis 
Nuclear division 
M phase of mitotic cell cycle 
Organelle fission 
Cell cycle, mitotic pathway 
Intracellular organelle lumen 
Membrane-enclosed lumen 
Organelle lumen 
Nuclear lumen 
Non-membrane-bounded organelle 
Intracellular non-membrane-bounded organelle 
DNA metabolic process 
Condensed chromosome 
Cell division 
Chromosome 
Spindle 
Chromosomal part 
Chromosome, centromeric region 
DNA replication 
Condensed chromosome, centromeric region 
Cell cycle pathway 
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Nucleolus 
Regulation of cell cycle 
Condensed chromosome kinetochore 
Response to DNA damage stimulus 
Nucleoplasm 
Spindle pole 
Microtubule cytoskeleton 
Chromosome segregation 
Kinetochore 
Cell cycle checkpoint 
Microtubule cytoskeleton organization 
Microtubule-based process 
DNA repair 
Mitotic sister chromatid segregation 
Sister chromatid segregation 
Chromosome organization 
Spindle microtubule 
Regulation of mitotic cell cycle 
Regulation of cell cycle process 
Cellular response to stress 
Mitotic cell cycle checkpoint 
DNA-dependent DNA replication 
Spindle organization 
Cell cycle checkpoints pathway 
Nuclear chromosome 
ATP binding 
Nucleoside binding 
Adenyl nucleotide binding 
Adenyl ribonucleotide binding 
Cytoskeletal part 
Purine nucleoside binding 
Interphase of mitotic cell cycle 
Interphase 
Macromolecular complex subunit organization 
DNA replication pathway 
Pyrimidine metabolism pathway 
Ribosome biogenesis 
Purine nucleotide binding 
DNA replication pathway 
Ribonucleotide binding 
Purine ribonucleotide binding 
Microtubule organizing center 
Ribonucleoprotein complex biogenesis 
NCRNA processing 
DNA integrity checkpoint 
DNA binding 
Nucleotide binding 
DNA packaging 
DNA strand elongation during DNA replication 
Microtubule 
RNA processing 
Meiotic cell cycle 
Macromolecular complex assembly 
Centrosome 
DNA strand elongation 
Condensed nuclear chromosome 
Regulation of organelle organization 
DNA damage checkpoint 
Regulation of ubiquitin-protein ligase activity during mitotic cell cycle 
Ncrna metabolic process 
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Protein targeting to mitochondrion 
Protein localization in mitochondrion 
Meiosis 
M phase of meiotic cell cycle 
tRNA processing 
Regulation of protein ubiquitination 
Regulation of nuclear division 
Regulation of mitosis 
Regulation of ubiquitin-protein ligase activity 
P53 signaling pathway 
Regulation of ligase activity 
Role of brca1, brca2 and atr in cancer susceptibility pathway 
Telomere maintenance pathway 
Cytoskeleton 
Lagging strand elongation 
Mitochondrion organization 
Chromosome condensation 
Cytoskeleton organization 
Phosphoinositide-mediated signaling 
Ribonucleoprotein complex 
Anaphase-promoting complex-dependent proteasomal ubiquitin-dependent 
protein catabolic process 
Negative regulation of ubiquitin-protein ligase activity during mitotic cell cycle 
Negative regulation of ligase activity 
Negative regulation of ubiquitin-protein ligase activity 
Oocyte meiosis pathway 
Mitotic chromosome condensation 
Spindle pole body 
Replication fork 
DNA repair pathway 
Chromatin 
Negative regulation of protein ubiquitination 
Establishment of chromosome localization 
Mitotic spindle organization 
Chromosome localization 
Protein complex assembly 
Protein complex biogenesis 
Microtubule organizing center part 
Kinetochore microtubule 
Cell proliferation 
DNA replication initiation 
Regulation of cyclin-dependent protein kinase activity 
Nucleotide-excision repair 
DNA damage response, signal transduction 
Apc-cdc20 mediated degradation of nek2a pathway 
Flap endonuclease activity 
Condensin complex 
Positive regulation of protein ubiquitination 
Nuclear chromosome part 
Mitochondrion 
Nucleotidyltransferase activity 
Nuclease activity 
Mitochondrial matrix 
Mitochondrial lumen 
Double-strand break repair 
RNA polymerase activity 
DNA-directed RNA polymerase activity 
TRNA metabolic process 
Protein serine/threonine kinase activity 
Nucleoplasm part 
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Cellular macromolecular complex subunit organization 
Negative regulation of protein modification process 
Protein targeting 
G2 phase of mitotic cell cycle 
G2 phase 
Organelle localization 
rRNA processing 
Regulation of microtubule cytoskeleton organization 
Microtubule binding 
Regulation of mitotic metaphase/anaphase transition 
Positive regulation of protein modification process 
Positive regulation of ubiquitin-protein ligase activity during mitotic cell cycle 
RRNA metabolic process 
Covalent chromatin modification 
Mitochondrial transport 
Establishment of organelle localization 
Biopolymer methylation 
Establishment of mitotic spindle localization 
Chromatin assembly or disassembly 
Positive regulation of ubiquitin-protein ligase activity 
Purine metabolism pathway 
Helicase activity 
Microtubule motor activity 
Brca1-dependent ub-ligase activity pathway 
Phospho-apc/c mediated degradation of cyclin a pathway 
Chromatin organization 
Protein import 
Positive regulation of cellular protein metabolic process 
Positive regulation of ligase activity 
Mitotic metaphase plate congression 
Proteasomal ubiquitin-dependent protein catabolic process 
Proteasomal protein catabolic process 
Structure-specific DNA binding 
RNA modification 
Regulation of microtubule-based process 
Methylation 
Base-excision repair 
Deoxyribonucleotide metabolic process 
Chromatin binding 
Protein kinase activity 
Spindle localization 
Establishment of spindle localization 
Positive regulation of protein metabolic process 
Nuclear matrix 
Centriole 
DNA-dependent atpase activity 
Cellular component disassembly 
Cajal body 
Mitotic cell cycle spindle assembly checkpoint 
Metaphase plate congression 
Negative regulation of mitotic metaphase/anaphase transition 
Base excision repair pathway 
One-carbon metabolic process 
Negative regulation of cellular protein metabolic process 
Positive regulation of organelle organization 
RNA binding 
Deoxyribonuclease activity 
Cellular protein localization 
Nuclear periphery 
Regulation of exit from mitosis 
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Negative regulation of nuclear division 
Negative regulation of mitosis 
Spindle checkpoint 
Pronucleus 
Cluster 3 
Di-, tri-valent inorganic cation homeostasis 
Cation homeostasis 
Cellular di-, tri-valent inorganic cation homeostasis 
Cellular cation homeostasis 
Intracellular signaling cascade 
Fc gamma r-mediated phagocytosis pathway 
Ion homeostasis 
Response to organic substance 
Cellular calcium ion homeostasis 
Calcium ion homeostasis 
Cellular metal ion homeostasis 
Cellular ion homeostasis 
Cellular chemical homeostasis 
Metal ion homeostasis 
Chemical homeostasis 
Response to wounding 
Cluster 4 
Proteinaceous extracellular matrix 
Extracellular matrix 
Extracellular region part 
Extracellular region 
Extracellular matrix part 
Response to wounding 
Collagen 
Cell adhesion 
Biological adhesion 
Extracellular space 
Calcium ion binding 
Collagen metabolic process 
Multicellular organismal macromolecule metabolic process 
Basement membrane 
Inflammatory response 
Multicellular organismal metabolic process 
Ecm-receptor interaction pathway 
Smad binding 
Protein dimerization activity 
Metalloendopeptidase activity 
Skeletal system development 
Blood vessel development 
Collagen catabolic process 
Vasculature development 
Regulation of cell proliferation 
Muscle cell differentiation 
Defense response 
Multicellular organismal catabolic process 
Collagen fibril organization 
Protein heterodimerization activity 
Focal adhesion pathway 
Endopeptidase activity 
 
The DAVID analysis (table 12) showed that the Cluster I consist of 117 genes was 
significantly (p-value <0.01) enriched with lipid biosynthesis process, sodium 
channel regulatory activity, positive regulation of metabolic process, digestion, 
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cellular respiration and inorganic anion transport GO terms. Hierarchical 
clustering analysis shows that majority of genes from this cluster were up-
regulated in C2 and C4 subtypes of colon cancers. We also observed PPAR 
signalling and mitochondrial carnitine palmitoyltransferase (cpt) system pathways 
contributed by PPARA, HMGCS2, FABP1, PCK2, CPT1A and ACSS2 genes. 
Cluster II: is the largest clusters identified by hierarchical clustering consist of 348 
genes and were up-regulated in a C5 subtype of colon cancers. We observed over-
representation of cellular processes such as cell cycle, metabolic processes, cell 
division, DNA and RNA replication, cell cycle check points, chromosome 
organization, DNA repair, ATP binding, DNA and RNA processing, and signal 
transduction. The cluster genes also showed enrichment of cell cycle, mitotic, cell 
cycle, DNA replication, pyrimidine replication, DNA repair, CDC20 mediated 
degradation of Nek2A, the role of BRCA1, BRCA2 and ATR in cancer 
susceptibility and p53 signalling pathways. 
 
4.2.9 Prognostic miRNAs and their impact on signatures of colon subtypes  
To gain further understanding into the biological impact of the identified 
prognostic miRNAs, we investigated their relationships with their putative targets 
and interaction pathways with in the mRNA expression data. We calculated the 
correlation between miRNA expression and their putative targets across all the 
tumour samples and identified top miRNA:mRNA pairs. In our results, we 
observed a clear separation between “protective” and “risk-associated” miRNAs 
and their associated target genes and their functional pathways.  
We identified five prognostic miRNAs (hsa-miR-628-3p, hsa-miR-135a*, hsa-
miR-183*, hsa-miR-330-5p, and hsa-miR-655) linked to “risk-associated” or 
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worse outcome target genes from C4 and C5 colon subtype. Enrichment analysis 
of genes in C4 and C5 subtypes have shown that unfavourable prognostic 
miRNAs are broadly related to cell cycle processes important for apoptosis and 
anti-proliferative activities such as DNA replication, DNA repair, DNA binding, 
ATP binding and pyrimidine binding. Other important pathways related to 
pyrimidine metabolism, oocyte meiosis, focal adhesion, ECM-receptor 
interaction, p53 signalling and telomere maintenance, a significant sub-pathway 
associated with colon cancer risk (Slattery et al., 2015b).  
Similarly, we observed five miRNAs (hsa-miR-378*, hsa-miR-15b*, hsa-miR-
323-3p, hsa-miR-125a-3p, and hsa-miR-92a-1*) associated with “protective” 
outcome have shown correlation with the up-regulatory genes of C5 and C2 
subtype of colon cancer. The biological theme positively correlated with 
favourable prognostics miRNAs were sodium channel regulatory activity, 
transmembrane transporter activity, cellular respiration, PPAR signalling pathway, 
cell division, DNA replication, DNA repair and metabolism.  
4.2.10 Subtype-specific miRNAs and their impact on transcriptional phenotypes 
We investigated the expression of miRNAs among the different types (primary 
tumour and metastatic) of colon cancer in order to understand the phenomenon 
behind the establishment of a tumour transcriptional phenotypes. As discussed 
above, among the 17 dysregulated miRNAs between primary colon tumour and 
metastatic, 11 miRNAs have shown highest expression among the metastatic 
tissues. Notably, four prognostic miRNAs (has- miR-15b*, hsa-miR-378*, hsa-
miR-323-3p, hsa-miR-125a-3p) were up-regulated among a metastatic tumour and 
observed with favourable prognosis. All four miRNAs targets genes from cluster I 
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and II, modulating important processes of transmembrane activity, PPAR 
signalling, DNA replication and DNA repair.     
Likewise, the two prognostic miRNAs (hsa-miR-135a*, hsa-miR-655) were 
highly up-regulated in primary colon tumours associated with worse prognosis, 
targets genes from cluster II and IV controlling important processes of cell cycle 
such as DNA replication, binding and repair, and p53 signalling pathway. 
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4.3 Discussion  
Prognostic stratification of the colon in clinical practice on the basis of gene 
expression has been proven unreliable to date largely due to the heterogeneity of 
colon cancer. Another challenging factor among colon cancers is to determine 
phenomenon behind molecular alterations of primary colon cells towards 
metastatic capability. In this study, we have performed robust classification of 
mRNA expression of a colon tumour on the basis of the transcriptome to improve 
existing stratification of colon cancers and identify subtype-specific signatures 
targeted by a new class of regulators known as miRNAs. We further investigated 
miRNAs association with the possible outcome, targeted molecular pathways and 
novel biological markers for chemotherapy.  
We first performed differential expression analysis on the entire cohort of miRNA 
colon tumour on the bases of histopathological groups in order to stratify the 
colon cancers. In results, we identify 70 highly dysregulated genes that can 
differentiate between the primary colon and metastatic tissue classes, colon cancer 
on the bases of tumour grades, colon cancer on the basis of stage and colon 
cancers with adjuvant chemotherapy. Subsequently, we identified 10-miRNA 
signature that can distinguish between the “protective” and “risk-associated” 
prognostic miRNAs, will required further validation on independent data set. For 
the primary tumour mRNA, we first sub-classify 585 colon tumours into five 
subtypes based on expression similarities and then clustered the most 
discriminatory genes into four signatures. Through, target prediction analysis, we 
identified that the prognostic miRNAs target genes of these four signatures and 
control their involvement in molecular processes of the cell cycle and signalling 
pathways.   
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4.3.1 The miRNAs expression in primary and metastatic colon cancer 
11 miRNAs upregulated in metastatic versus primary tissues strictly represent 
metastatic pool of colon cancers for which the publicly available software mirPath 
(Vlachos et al., 2012) identified number of known biomarkers genes and modulate 
important pathways such as Neurotrophin signaling, MAPK signaling, TGF-beta 
signaling, Axon guidance, PI3K-Akt signaling, mTOR signaling, ErbB signaling, 
Chronic myeloid leukemia, Insulin signaling, p53 signaling and Colorectal cancer 
pathways. Therefore, the observed association of metastatic miRNAs with a large 
number of signalling pathways confirms the presence of metastatic lymph node 
RNAs and provide strong evidence of their potential role in the development of 
metastases. Among the dysregulated miRNAs, hsa-miR-15b is an interesting one 
and highly upregulated in metastatic compared to primary tissues. We have 
observed an association of hsa-miR-15b with high-risk survival in this study, 
modulate p53 tumour suppressor signalling pathway important for high metastatic 
potential and metastatic relapse.    
Similarly, 6 other miRNAs upregulated in primary tissues target functional 
pathways such as PI3K-Akt signaling, Focal adhesion, Ubiquitin mediated 
proteolysis, Regulation of actin cytoskeleton, Prostate cancer, mTOR signaling, 
Pathways in cancer, Melanoma, TGF-beta signaling, and ErbB signaling related 
pathways and thus expected to be involved in promoting proliferation and 
inhibiting apoptosis, and also play an important role in tumour microenvironment 
(Qiu et al., 2016, Aminuddin and Ng, 2016). Most of the miRNAs dysregulated 
have shown log fold change > 0.5 and some of them have been previously 
observed in relation to colon cancers such as hsa-miR-135a*, hsa-miR-26a, and 
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hsa-miR-335. However, mostly miRNAs associated with survival and metastases 
were not found in association with colon cancer before.   
4.3.2 miRNAs as prognostic markers in colon cancer  
Using univariate and multivariate Cox analysis we examined the correlation of 
differentially expressed miRNAs in colon tumour samples with OS and DFS. As a 
result, we observed 10 miRNAs prognostic signature for OS and DFS with 
“protective” and risky outcomes. The correlation analysis of prognostic miRNAs 
with targeted pathways provides indirect (independent) evidence of their 
association with the biology of a colon tumour. One of the themes related to risk-
associated miRNAs were the appearance of functional pathways such as TFG-
beta, T cell, Wnt, mTOR and ErbB signalling pathways vital for cell cycle 
progression, proliferation, apoptosis, differentiation and migration (Oh et al., 
2016, Aminuddin and Ng, 2016). The other emerging theme related to protective 
roles of miRNAs were the presence of cell cycle and related processes important 
for inducing apoptosis, cell cycle arrest and inhibition of cell migration (Wu et al., 
2016, Hu et al., 2016).    
We then focused on individual miRNAs for their impact on colon tumour 
microenvironment. Risk-associated miRNAs such as hsa-miR-628-3p, previously 
reported in association with a diagnostic marker for low-stage pancreatic cancer 
(Li et al., 2013) is highly upregulated among the stages comparison particularly in 
early stages (Stage I and II) of a colon tumour in our study. Integrated analysis 
demonstrated that the top anti-correlated targets genes for hsa-miR-628-3p were 
DNAJA3, PKP4, STK17B, GPR19, ASPM, FAM3D, SAMD13, and 
MARVELD3, belongs to Cluster I and II functional subgroups and specifically 
upregulated in C2, C4 and C5 subtypes of colon cancer. These genes are 
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potentially involved in important regulatory processes such as intracellular 
organelle lumen, membrane-enclosed lumen, organelle lumen and pathways of 
p53 signalling, PPAR signalling pathway, cell cycle and DNA repair. hsa-miR-
323-3p previously reported in association with metastases in pancreatic (Wang et 
al., 2016) and cervical squamous cell carcinoma (Ding et al., 2014)  has also 
shown over-expression metastatic tissue. From the integrated analysis, we also 
predicted gene targets AGT, E2F1, HK2, EXO1, TTK, DFFB, SPC25, OIP5, 
SELENBP1, NUSAP1, TIMM23, E2F8, SETD7, C9orf41 and CMTM8, involved 
in important processes of apoptosis, cell cycle, metabolism and mismatch repair. 
The analysis shows downregulation of all these predicted target genes and 
upregulation of hsa-miR-323-3p in metastatic tissue explains its “protective” role; 
most of these target genes belong to a C5 subtype of colon cancer. Another 
microRNA, hsa-miR-125a-3p predicting OS is upregulated in metastatic tissue 
defined as “protective”. Till date, nothing has been reported of hsa-miR-125a-3p 
in association with colon cancer but has been involved in multiple abnormalities 
(Huat et al., 2015, Bi et al., 2015, Tang et al., 2015). However, hsa-miR-125a-3p 
have been involved in its protective functions by increased apoptosis (Ninio-Many 
et al., 2014) and a wide range of biological processes including regulation of 
Wnt/beta-catenin signalling pathway (Choi et al., 2011). The upregulation of hsa-
miR-655 in metastatic tissues linked to “risk associated” overall survival. hsa-
miR-655 has been reportedly involved in a number of tumorigenesis and drug 
resistance. hsa-miR-655 regulate TGF-β-induced epithelial-mesenchymal 
transition, a key element of cell invasion, migration, metastases and drug 
resistance. Anti-correlation analysis shows that patients with upregulation of hsa-
miR-655 and downregulation of its targets mRNA genes carry the risk of 
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metastases. The potential target genes of hsa-miR-655 belong to subtype C2, C4 
and C5 of colon cancer.  
Prognostic marker for DFS, hsa-miR-92a-1* dysregulated among the histological 
grades, particularly upregulated among poor grades defined as “protective” in 
action. hsa-miR-92a-1* has been previously reported in connection with colorectal 
cancer by consistent amplification of MIR17HG, CMYC, and ABCC4 genes 
(Molinari et al., 2016). The anti-correlation analysis shows that hsa-miR-92a-1* 
targets TNC, RNASE1, CLDN7, KNTC1, KLC1, DUS1L, EXOSC5, and 
TMEM52 of C5 subtype of colon cancer, involved in processes like cell adhesion, 
RNA degradation and ECM-receptor interaction.  
4.3.3 How miRNAs expressed in different pathological groups? 
We have observed 70 miRNAs differentially expressed among the histological 
groups. We observed the highest number of dysregulated genes when we 
compared expression data among the three different grades. As anticipated, we 
observed a theme that those miRNAs which have shown upregulation among the 
metastatic tissues tend to over-expressed among the poorly differentiated grades 
and higher stages (III and IV). Such as hsa-miR-378* miRNA have shown higher 
expression among the metastatic tissue compared to primary colon has also 
highest expression level among the poorly differentiated grades and Stage III & 
IV. Likewise, other miRNAs such as hsa-miR-424* has also shown similar trends. 
The identified findings from this study are in agreement with independent studies 
(Schneider and Langner, 2014, Derwinger and Gustavsson, 2008) therefore shows 
the validity of confirmed the validity of histological based feature selection. These 
finding also reinforced the idea of RNA based classification at the miRNA level.  
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We have also found some of the miRNAs expression level was very specific to 
one histological group, indicate histological based targeting of mRNA and 
oncogenic pathways. We have found 7 miRNAs specifically belongs to primary 
colon versus metastatic group and most of them have shown downregulation in 
metastatic tissues. Further investigation on individual miRNA may highlight 
factors behind metastases. Similarly, we identify 12 miRNAs specific to Stages 
comparison only and most of these miRNAs have shown over-expression among 
the early Stages (I and II) of colon tumours. Therefore, stage level based miRNA-
mRNA associations can be major contributors of different transcription 
phenotypes.  
In conclusion, we have performed miRNA, mRNA integration with pathological 
and clinical information of well-characterised cohorts of colon cancers. This study 
present advance histological based classification of miRNA expression data and 
their role in regulating subtype-specific transcriptional signatures. Furthermore, 
we have classified primary colon into five major subtypes on the bases of their 
RNA levels and also divided five subtypes and four functional groups on the basis 
of their involvement function pathways. We have also provided a dissection of 
aberrations at the miRNA level, their impact on targets and perturbations among 
functional pathways.                
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4.4 Methods 
4.4.1 Data collection and preprocessing 
Both expression data sets consist of miRNA and mRNA profiles were extracted 
from GEO (Gene Expression Omnibus). miRNA expression was extracted from 
FFPE colon tissues for microRNA array analysis using NIH Taqman Human 
MicroRNA Array v.2 platform can be found under the accession number 
GSE29622. The miRNA expression set consist of 47 primary and 18 metastatic 
colon cancers with patient follow-up and extensive histopathological information. 
Likewise, mRNA expression data set consists of 598 colon cancer samples 
analysed using Affymetrix U133plus2 chip profiles can be found under the 
Subseries accession number GSE39582. 
We applied functions of Bioconductor GEOquery package (Davis, 2013) for the 
extraction of raw expression data for both types of RNA sets. Various functions of 
Robust Multichip Analysis (RMA) methodology were applied for background 
correction followed by quantile normalisation for the correction of inter-arrays 
global differences. All the probes with Zero variance were filtered for further 
analysis. R, Hclust functions were used for the calculation of two-dimensional 
average-linkage hierarchical clustering and heatmaps were drawn using rows as 
scale.  
4.4.2 Statistical analysis 
We applied Cox-regression analysis for the calculation of association of miRNA 
level expression with disease-free survival (DFS) and overall-survival (OS) 
followed by adjustment of wald test p-values using multiple-testing using 
Benjamin-Hochberg method. We consider all those miRNAs were having 
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threshold value less than 0.05 associated with DFS and OS. Survival data were 
censored at the date of alive/death from any cause for OS and the evidence of 
recurrence or no recurrence for DFS. We applied different Cox-regression models 
for histopathological covariates, grouped as Gender (male or female), Tumour 
Type (a primary tumour versus metastatic), Grades (continuous), Stage 
(continuous) Adjuvant Chemotherapy (no or yes). Survival curves were calculated 
and drawn by Kaplan-Meier analysis using R analysis “survival” tools.  
4.4.3 Identification of dysregulated miRNAs linked to specific colon subtypes 
We applied ANOVA and on some instance Student’s t-test for the identification of 
differentially expressed miRNAs across the different histological groups such as 
(primary versus metastatic) (well versus moderate versus poorly grades), among 
the stages, and (adjuvant chemotherapy yes versus no). All the obtained p-values 
were adjusted for multiple testing using False Discovery Rate using threshold 
value (q-value < 0.01) for differentially expressed genes.  
4.4.4 Collection of miRNAs targets and independent correlation analysis 
In order to perform integration analysis, we collected candidate targets for each 
miRNAs using six different databases (TargetScan, TarBase, PicTar, mirBase, 
miRTarget2, miRanda) using R Bioconductor package “RmiR”. We performed 
independent correlation analysis among the miRNAs and their particular targets in 
order to evaluate the influence of each miRNA. We selected the top anti-
correlated miRNA-mRNA pairs for further analysis.  
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4.4.5 Classification of primary colon into subtypes and identification of functional 
signatures 
We performed unsupervised K-mean consensus clustering using 
‘ConsensusClustering’ package of R Bioconductor for the identification of 
potential subtypes of a colon tumour. We run values starting from K=2 to K=6 in 
core K-mean clustering. A highest consensus score was used for the selection of a 
number of classes followed by ANOVA analysis for the identification of 
dysregulated genes among the intrinsic subtypes. Again, p-values were adjusted 
using False Discovery Rate and mRNA genes exhibiting q-value less than 0.001 
termed as significant.  
4.4.6 Functional analysis  
In order to identify perturbed functional pathways of gene signatures, we applied 
functional classification tools of available databases such as KEGG (Kanehisa et 
al., 2016), Reactome (Fabregat et al., 2016) and DAVID (Huang et al., 2009a). 
Threshold p-value less than 0.001 was used for the selection of significant 
processes, molecular functions and pathways.  
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CHAPTER 5 CONCLUSIONS AND FUTURE WORK 
5.1 Conclusions 
The main objective of this report is to discuss the latest development involving the 
application of DNA microarray on colon cancer and to address the key problems 
in precise and early targets for diagnosis, distinctive molecular classes and clinical 
outcome. The discovery of DNA microarray has offered tremendous tools such 
profiling of gene expression which expanded exponentially in the last decade. 
DNA microarray also showed enormous impact on the identification of gene 
expression signature vital for early predictions and clinical outcome of multiple 
cancer types. One of the major challenges in microarray data analysis is a small 
number of samples size in given study compare to a large number of driving 
variable of cancer. Small sample size not only made interpretation difficult but 
model development, considering the heterogeneous nature of cancer. So, it is not 
surprising that there is an only small convergence between the gene signatures 
from different investigators discussing colon cancer. 
In chapter 2 of the thesis, we highlighted major advancement in the area of colon 
cancer. We showed that number of studies have been conducted in order to 
classify colon tumours into subtypes and novel drug targets for the clinical use. 
We highlighted the earliest method used in the selection of therapeutic targets for 
colon cancer was the discovery of gene-drug correlation. We have also seen that 
colon cancer was subjected to classification on the basis of phenotypes based on 
microsatellite instability (MSI), phenotypes based on the genetic aberrations were 
presence of genes such as KRAS or BRAF, and phenotypes based on functional 
pathways were presence of Wnt/ß-catenin, TGF-ß, MAPK, and PI3K signaling. 
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We also discussed that most of the studies were conducted focusing on individual 
gene 
targets rather than covering all other aspects of heterogeneity. Some of the author 
in the past have utilised molecular level similarities in the identification of specific 
pathways affected in diseases, in the identification drug targets and designing of 
survival outcome classifiers. One of the major contribution offered by a group of 
Cancer Genome Atlas by performing genome-scale analysis of 276 patients. As 
result, they observed a number of important genes and critical pathways required 
for the initiation and progression of colon cancers. Some of the significant 
findings from this study was the discovery of P53, PI3K, RAS-MAPK, TGF-β, 
WNT, and DNA mismatch repair pathways. In spite of such progress, there are 
still some unknown genetic and genomic changes which play a significant role in 
colon tumorigenesis. 
In chapter 3 of the thesis, the identification of molecular markers with prognostic 
value in colorectal cancer is a challenging task that is needed to define therapeutic 
guidelines. Despite recent advances in the screening, diagnosis, and treatment of 
colorectal cancer, an estimated 608, 000 people die every year from this form of 
cancer, which is 8% of all cancer deaths. We performed two staged integrated 
bioinformatics analytics on gene expression data sets of three latest developed 
studies of colon cancer. We identified two groups of integrated signatures from 
the comparison of normal versus a tumour and tumour versus meets patient’s 
samples. Functional analysis of the diagnostics 267-genes shows over-
representation of signaling-related molecules and also significantly involved in 
cancers related regulatory pathways. The metastatic 124-gene signature shows 
functionally involved in immune-response, lipid metabolism and PPAR signalling 
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pathways. Kaplan-Meier estimates of 124-genes using independent data sets 
shows that higher grade/stage patients have significantly better overall-survival 
(p=0.001, 
HR=2.61(CI 1.43-4.79)) and disease-specific survival rate (p=0.00, HR=2.41(CI 
1.28-4.53)) compare to low grade patients. Further biological validation of genes 
identified in this study may provide vital biomarker targets for colon cancers. 
In chapter 4 of the thesis, we have performed miRNA, mRNA integration with 
pathological and clinical information of well-characterised cohorts of colon 
cancers. This study present advance histological based classification of miRNA 
expression data and their role in regulating subtype-specific transcriptional 
signatures. Furthermore, we have classified primary colon into five major 
subtypes on the bases of their RNA levels and also divided five subtypes and four 
functional groups on the basis of their involvement function pathways. We have 
also provided a dissection of aberrations at the miRNA level, their impact on 
targets and perturbations among functional pathways. 
In summary, we have identified robust and reliable signatures of miRNA and 
mRNA along with the identification of distinct subtypes of a colon tumour. 
Another advantage of this study is that we have uncovered genomic features 
which may have been remained undetected in individual studies and have an 
important role in tumour progression. 
5.2 Future Work 
The data integration models have produced promising results for the colon cancer 
diagnostic and prognostic signature identification. The two independent studies 
focusing on tissue-based integration method and integration of two different levels 
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have established workflow models which can be applied on any independent 
population. Our main focus was to identify diagnostic and prognostic signatures 
by integrated analysis without losing potential signature genes. 
In a complex disease such as colon cancer, there are the only limited amount of 
microarray data generated from some platform from different studies addressing a 
similar question. In this situation, we can have considered tissue-based integration 
method for different generations of the same microarray technology or for the data 
generated from multiple microarray platforms. The models proposed in this thesis 
can then be applied to the integrated data sets of the list of common genes to 
increase statistical power and to derive reliable gene signatures. In this way, we 
gain statistical power at the price of loss of potential signature genes. 
By using the miRNA-mRNA integrative analysis model, we can integrate two 
different Omics data levels with clinical and pathological data for the accurate 
prediction of phenotypic outcome. This could lead to improved cancer prognostic 
signatures which are mixtures of epigenetic factors, gene expression and clinical 
parameters. Furthermore, other high-throughput data, such as single nucleotide 
polymorphism, copy number variation, protein expression data, structural data and 
tissue microarray data, can be effectively combined into the integrated microarray 
data in similar manners to correlate changes in gene expression profiles with 
changes in proteomic or phenotypes. 
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